A. EXTENT OF DRUG USE

Overall drug use remains stable globally

It is estimated that almost a quarter of a billion people between the ages of 15 and 64 years used an illicit drug in 2013. This corresponds to a global prevalence of 5.2 per cent (range: 3.4-7.0 per cent), suggesting that drug use has remained stable in the past three years, although the estimated number of drug users has actually risen by 6 million to 246 million (range: 162 million-329 million) owing to the increase in the global population. With some 27 million people (range: 15.7 million-39 million), or 0.6 per cent of the population aged 15-64, estimated to suffer from problem drug use, including drug-use disorders or drug dependence, problem drug use seems to have remained somewhat stable over this three-year period.

### TABLE 1. Global estimates of the use of various drugs, 2013

<table>
<thead>
<tr>
<th>Drug</th>
<th>Percentage of population that has used the drug</th>
<th>Number of users (thousands)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>low</td>
<td>high</td>
</tr>
<tr>
<td>Cannabis</td>
<td>2.7</td>
<td>4.9</td>
</tr>
<tr>
<td>Opioids</td>
<td>0.6</td>
<td>0.8</td>
</tr>
<tr>
<td>Opiates</td>
<td>0.3</td>
<td>0.4</td>
</tr>
<tr>
<td>Cocaine</td>
<td>0.3</td>
<td>0.4</td>
</tr>
<tr>
<td>Amphetamines</td>
<td>0.3</td>
<td>1.1</td>
</tr>
<tr>
<td>“Ecstasy”-group</td>
<td>0.2</td>
<td>0.6</td>
</tr>
<tr>
<td>All illicit drug use</td>
<td>3.4</td>
<td>7.0</td>
</tr>
</tbody>
</table>

Source: UNODC, responses to annual report questionnaire.
Note: Estimates for adults aged 15-64, based on past-year use.
Global and regional trends in drug use are estimated from nationally representative surveys that include questions on drug use, as well as from information gathered through studies that use indirect methods to estimate the number of regular or high-risk users such as problem opioids users. Household surveys on drug use are expensive and, at best, carried out every three to five years. Many countries do not conduct such surveys on a regular basis and many others, especially in Asia and Africa, do not conduct them at all. In these cases, estimates from the limited number of countries where data are available are used to compute regional and global estimates.\(^a\)

Rather than real-time trends at the global and regional levels, year-on-year changes in drug-use estimates thus reflect updated information from countries where new data were made available. These changes may be especially misleading if updated information is available only in countries with large populations. Indeed, global and regional estimates of drug use, including by substance, are heavily shaped by countries with large populations because of the use of national drug-use data weighted by population size in the calculation of the estimates. The stable trend that can be calculated with existing data, may mask variations that are happening in large countries for which data are not available. In addition, the estimated number of drug users is further influenced by changes in estimates of the global population aged 15-64.

The global and regional estimates of the extent of drug use offered in the present report should be viewed as best estimates, noting that they reflect the best available information at the time of analysis. From a global policy perspective, it would be more prudent to look at long-term trends rather than year-on-year changes, which may be merely a reflection of changes in a few countries. Furthermore, particular caution is required when considering trends in problem drug-use estimates at the global level, as the extent of problem drug use is difficult to capture in general population surveys (which are used to estimate drug use), and indirect methods, which are often complex, are therefore used to obtain these estimates.

Notwithstanding both regional and national variations in trends in the use of different types of drug, cannabis use has continued to rise since 2009, while the use of opioids, including the use of heroin, opium and the non-medical use of pharmaceutical opioids, has stabilized at high levels (see figure 3). However, the use of cocaine and amphetamines has declined overall, although that is mainly a reflection of trends in the Americas and Europe.

Problem drug use as reflected in the demand for drug treatment

In the absence of data on patterns of problem drug use, data on drug users in treatment are taken as a proxy. Treatment demand for different substances varies by region, but almost half of the people who access treatment for drug use are first-time entrants. The proportion of first-time entrants in treatment for ATS and cannabis use disorders in 2013 was higher than for other substances in most regions, indicating that, compared with other substances, there is an expanding generation of ATS and cannabis users who need treatment (see figure 4). In Asia, the number of people accessing treatment for cannabis-use disorders is small, but the proportion of first-time entrants among them (62 per cent) is the largest. Compared with other regions where cannabis users in treatment are typically in their twenties, in Asia they are reported to be typically in their thirties. As observed elsewhere,\(^1,2\) this may reflect a cohort of long-term regular users of cannabis who seek treatment for cannabis-related problems. In Europe, North America and Oceania, the proportion of first-time entrants for cannabis-use disorders is high, but they tend to be in their twenties. A large share of cannabis users in treatment may reflect cannabis users referred by the criminal justice system, whereas opioid users in treatment are relatively older (in their thirties). In Western and Central Europe, 16 per cent of first-time entrants were seeking treatment for opioid use, and overall treatment demand remains high, which reflects an ageing cohort of opioid users in treatment: of the estimated 1.5 million opioid users in Europe, 700,000 received opioid substitution therapy in 2012.\(^3\) The high proportion of people in treatment for opioid use in Asia and Eastern Europe reflects the extent of problem opioid use in those regions, and ATS users form another group with a high proportion of first-time entrants in treatment in Asia.

---

\(^{1}\) Alan J. Budney and others, “Marijuana dependence and its treatment”, *Addiction Science and Clinical Practice*, vol. 4, No. 1 (December 2007), pp. 4-16.


Prison is a high-risk environment for drug use

On any given day, more than 10.2 million people are held in penal institutions throughout the world, mostly as pre-trial detainees or remand prisoners, or as sentenced prisoners. However, because of the high transfer of people between prison and the wider community, the number of people who spend at least some time in prison each year is considerably greater. The rapid turnover of a large number of people between the prison environment and their wider communities outside prison means that prison health merits consideration as an integral part of public health.

Drug use, including heroin use, and drug injection are common in prisons

People who use drugs often have a history of incarceration. In the United States of America, for example, it is estimated that between 24 and 36 per cent of all people using heroin pass through the correctional system each year, representing more than 200,000 individuals. Although data remain limited, studies have shown that drug use within prisons is common (see figure 5). Based on a review of 41 studies from 26 countries (mostly in Europe) and supplemented with data reported in responses from Member States to the annual report questionnaire, drug use in prisons was shown to be highly prevalent in many of these studies, although there is considerable variability. Approximately one in three people held in prison have used drugs at least once while incarcerated, with approximately one in eight reporting use in the past month. Cannabis is the most commonly used drug, as it is in the wider community outside prison, but lifetime and recent (past-month) use of heroin in prison is more common than that of cocaine, amphetamines or “ecstasy”. Based on these studies, the median estimate of the proportion of people held in prison who have used heroin at some time while incarcerated is 10.1 per cent (inter-quartile range: 2.5-13.4 per cent), while 5.0 per cent (inter-quartile range: 0.8-11.5 per cent) report use in the past year (which is approximately 14 times higher than in the general population, estimated at 0.35 per cent), and 2.4 per cent (inter-quartile range: 1.3-9.0 per cent) report recent use in the past month.

A number of studies report high levels of injecting drug use by prisoners, which may be a result of the high prevalence of heroin use. In Europe, of the 12 countries reporting to EMCDDA on injecting drug use by prisoners at some time during incarceration, four countries report...
levels above 10 per cent (Luxembourg, 31 per cent; Germany, 22 per cent; Portugal, 11 per cent; and Latvia, 10 per cent). Some small-scale surveys provide anecdotal information on high levels of injecting drugs in prison. For example, among a survey of female prisoners in British Columbia, Canada, 21 per cent reported injecting drugs while in prison; a survey of prisoners in Australia revealed that 23 per cent had injected drugs at some time in prison; and among male inmates in Bangkok, 39 per cent reported injecting drugs while in prison, with 12 per cent injecting for the first time while incarcerated. These estimates are considerably higher than the prevalence of injecting drug use among the general population, which is estimated globally to be 0.26 per cent of those aged 15-64.

Unsafe injecting practices are a major risk factor for the transmission of blood-borne infections such as HIV and viral hepatitis B and C. Due to the difficulties of obtaining sterile needles and syringes, people held in prisons are more likely to share injecting equipment and this practice has been found to be extremely common among prisoners. Very high levels of sharing of needles and syringes have been documented among people who inject drugs (PWID) in prisons: 56 per cent in Pakistan, 66 per cent in the Russian Federation, 70-90 per cent in Australia, 78 per cent in Thailand and 83-92 per cent in Greece.

B. HEALTH IMPACT OF DRUG USE

Millions of people inject drugs worldwide

Among people using drugs, PWID are one of the most vulnerable and marginalized groups. They experience a range of health, socioeconomic and legal challenges, often with poor outcomes, not least of which is the elevated risk of death compared with the general population (see also box 3). The joint UNODC/WHO/UNAIDS/World Bank estimate for the number of PWID worldwide for 2013 is 12.19 million (range: 8.48-21.46 million). This corresponds to 0.26 per cent (range: 0.18-0.46 per cent) of the adult population aged 15-64. This estimate is based on reporting of information on current injecting drug use from 93 countries covering 84 per cent of the global population aged 15-64.
The updated global total number of PWID is slightly different from the 12.69 million (for 2012) published in the World Drug Report 2014. Although new or more recent information on PWID from 22 countries are included, the revision primarily reflects new estimates for Poland and the United Republic of Tanzania, which were not previously reported, and lower estimates for the numbers of PWID in Brazil and Viet Nam. The global prevalence of PWID among the population aged 15-64 is essentially unchanged from the World Drug Report 2014.

By far the highest prevalence of PWID continues to be found in Eastern and South-Eastern Europe, where 1.27 per cent of the general population aged 15-64 is estimated to be injecting drugs, a rate nearly five times the global average. The estimate for this subregion is heavily influenced by the high prevalence of injecting drug use experienced in the Russian Federation (2.29 per cent of the population aged 15-64). However, in terms of the actual numbers of PWID, the largest proportion continues to reside in East and South-East Asia, with an estimated 3.15 million, accounting for approximately one in four PWID worldwide. Large numbers of PWID also reside in Eastern and South-Eastern Europe (2.91 million, representing 24 per cent of the global total number of PWID) and North America (2.07 million, representing 17 per cent of the global total number of PWID). Three countries, the Russian Federation, China and the United States, when combined, account for nearly half (48 per cent) of the global total number of PWID.
The burden of HIV among people who inject drugs continues to be high in many regions

The burden of HIV among PWID is high, with PWID accounting for an estimated 30 per cent of new HIV infections outside sub-Saharan Africa. About 1.65 million (range: 0.92-4.42 million) PWID were estimated to be living with HIV in 2013, which would correspond to 13.5 per cent of PWID being HIV positive. This joint UNODC/WHO/UNAIDS/World Bank estimate is based on information on the prevalence of HIV among PWID from 114 countries, covering 93 per cent of the estimated global number of PWID.

Although estimates of the prevalence of HIV among PWID have been updated for 52 countries (none with large numbers of PWID living with HIV), the global total number of PWID living with HIV is essentially unchanged from the information provided in the World Drug Report 2014. However, the small downward revision to the total number of PWID globally has resulted in the overall prevalence of HIV among PWID being revised upwards to 13.5 per cent (from the 13.1 per cent presented in the World Drug Report 2014).

Two subregions stand out as having particularly high rates of HIV infection among PWID. An estimated 29 per cent of PWID are living with HIV in South-West Asia and some 23 per cent of PWID are living with HIV in Eastern and South-Eastern Europe. In the remaining regions, the average prevalence of HIV infection among PWID is much lower, ranging from 1 per cent in Oceania to 11 per cent in Africa (although for Africa this estimate may not be reliable as monitoring systems may not be adequate).

Approximately 40 per cent of the estimated global total number of PWID living with HIV in Eastern and South-Eastern Europe, mostly in the Russian Federation and Ukraine. East and South-East Asia contribute a further 20 per cent to the total global number of PWID living with HIV, although both the prevalence of injecting drug use and the prevalence of HIV among PWID are below their respective global averages. It is the large population aged 15-64 residing in this region that translates into the relatively large number of PWID living with HIV. South-West Asia, the region with the highest prevalence of HIV among PWID, contributes 12 per cent to the total global number of PWID living with HIV, with a large proportion of these residing in Pakistan. Four countries, the Russian Federation, China, Pakistan and the United States (in descending order), when combined account for nearly two thirds (65 per cent) of the total global estimated number of PWID living with HIV.
TABLE 3. Estimated number and prevalence (percentage) of HIV among people who inject drugs, 2013

<table>
<thead>
<tr>
<th>Region</th>
<th>Subregion</th>
<th>Estimated number</th>
<th>Prevalence (percentage)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>low</td>
<td>best</td>
</tr>
<tr>
<td>Africa</td>
<td></td>
<td>30,000</td>
<td>112,000</td>
</tr>
<tr>
<td>America</td>
<td></td>
<td>167,000</td>
<td>237,000</td>
</tr>
<tr>
<td>North America</td>
<td></td>
<td>141,000</td>
<td>182,000</td>
</tr>
<tr>
<td>Latin America and the Caribbean</td>
<td></td>
<td>26,000</td>
<td>55,000</td>
</tr>
<tr>
<td>Asia</td>
<td>Central Asia and Transcaucasia</td>
<td>26,000</td>
<td>31,000</td>
</tr>
<tr>
<td></td>
<td>East and South-East Asia</td>
<td>211,000</td>
<td>329,000</td>
</tr>
<tr>
<td></td>
<td>South-West Asia</td>
<td>90,000</td>
<td>196,000</td>
</tr>
<tr>
<td></td>
<td>Near and Middle East</td>
<td>1,000</td>
<td>3,000</td>
</tr>
<tr>
<td></td>
<td>South Asia</td>
<td>17,000</td>
<td>17,000</td>
</tr>
<tr>
<td>Europe</td>
<td>Eastern and South-Eastern Europe</td>
<td>322,000</td>
<td>665,000</td>
</tr>
<tr>
<td></td>
<td>Western and Central Europe</td>
<td>51,000</td>
<td>59,000</td>
</tr>
<tr>
<td>Oceania</td>
<td></td>
<td>1,000</td>
<td>1,000</td>
</tr>
<tr>
<td>GLOBAL</td>
<td></td>
<td>915,000</td>
<td>1,651,000</td>
</tr>
</tbody>
</table>

Sources: UNODC, responses to annual report questionnaire; progress reports of UNAIDS on the global AIDS response (various years); the former Reference Group to the United Nations on HIV and Injecting Drug Use; estimates based on UNODC data; and national government reports.

Note: Numbers are rounded to the nearest 10,000.

FIG. 6. People who inject drugs living with HIV, in relation to the prevalence (percentage) of people who inject drugs and the prevalence (percentage) of HIV among this group, by region, 2013

Prevalence of people who inject drugs among the general population aged 15-64 (percentage)

Sources: UNODC; responses to annual report questionnaire; progress reports of UNAIDS on the global AIDS response (various years); the former Reference Group to the United Nations on HIV and Injecting Drug Use; and national government reports.

Notes: The number of PWID living with HIV is represented for each region as both a proportion of PWID in the general population aged 15-64 (horizontal axis) and as a proportion of PWID living with HIV (vertical axis). The areas of the circles are proportional to the number of PWID living with HIV. The orange dot and dashed lines represent the global average prevalence of PWID and the global average prevalence of PWID living with HIV.
PREMATURE DEATH IS COMMON AMONG PEOPLE WHO INJECT DRUGS

Compared with the general population, PWID are at an elevated risk of dying, primarily as a result of the transmission of infectious diseases, in particular HIV, and of fatal drug overdoses. A recent systematic review of cohort studies that followed PWID over time\(^a\) suggests that they experience a high mortality rate. The overall (pooled) mortality rate across the 65 cohort studies from 25 countries estimated a mortality rate of 2.35 deaths per 100 person-years (if 100 PWID were followed over one year, two to three deaths would be expected to occur among this group). This is a much higher level of mortality than among those of comparable age and gender among the general population (standardized mortality ratio = 14.68).

Mortality rates among people who inject drugs and the increase in mortality among people who inject drugs compared with the general population

Asia is the region with the largest estimated population of PWID, accounting for more than one in three PWID globally. Albeit based on a very limited number of studies, at 5.25 deaths per 100 person-years, the region also experiences a high mortality rate from injecting drugs. By contrast, findings from five other studies in Australia suggest that the level of mortality among PWID is low in Australia, at 0.71 deaths per 100 person-years.

The mortality rate was observed to be higher among males who inject drugs (MWID). Based on 37 studies, MWID were found to have a mortality rate 1.32 times that of females who inject drugs (FWID). However, based on 19 studies, FWID had a greater excess mortality than MWID when compared with similar age groups in the general population. Across 43 studies, the crude mortality rate among PWID from overdose was estimated at 0.62 deaths per 100 person-years.

Continuity of treatment and the length of time spent in treatment can have an impact in reducing overdoses among PWID. Data from six studies showed a risk of dying some 2.5 times higher for PWID during off-treatment periods compared with in-treatment time periods.

Effective evidence-based interventions can now be identified for prevention, treatment and care of HIV for PWID,\(^b\) including needle and syringe programmes, opioid substitution therapy, antiretroviral therapy and the availability of naloxone. For example, a recent systematic review\(^c\) highlighted the importance of opioid substitution therapy, finding that it is associated with an average 54 per cent reduction in the risk of new HIV infection among PWID, largely by reducing the frequency of unsafe injecting; this is ultimately very likely to reduce the number of deaths among PWID. However, the availability of evidence-based interventions targeting PWID, including opioid substitution therapy, varies considerably across countries and is generally limited even in countries with a high prevalence of PWID and high proportions of PWID who are living with HIV.\(^d\)

---


The Russian Federation is affected by a concentrated HIV epidemic among PWID. Approximately one in three PWID living with HIV worldwide are estimated to reside in the Russian Federation, which experiences both a high prevalence and a high incidence\(^\text{14}\) of HIV among PWID. However, across cities in the Russian Federation there is a very large variation in the HIV prevalence among PWID. A study carried out in eight cities in the period 2007-2009 showed percentages of PWID living with HIV ranging from levels below 10 per cent in Voro- nezh (3 per cent) and Omsk (9 per cent), to around 15 per cent in Naberezhnye Chelny (13 per cent), Chelyabinsk and Orel (both 15 per cent), to around 60 per cent in Irkutsk (57 per cent), Saint Petersburg (59 per cent) and Yekaterinburg (64 per cent).\(^\text{15}\)

The prevalence of HIV among PWID can vary markedly between cities (see figure 7) and certain cities and settings around the world that carry a large proportion of the global burden of HIV are becoming a focus of attention in the global response to the HIV epidemic,\(^\text{16}\) with the geographically localized nature of HIV epidemics and the role of cities and settings, such as prisons, increasingly being seen as critical considerations.

### FIG. 7. Prevalence of HIV among people who inject drugs in selected cities

<table>
<thead>
<tr>
<th>City</th>
<th>Prevalence (percentage)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Libya, Tripoli</td>
<td>87.1</td>
</tr>
<tr>
<td>Romania, Bucharest</td>
<td>53.3</td>
</tr>
<tr>
<td>Latvia, Riga</td>
<td>25.7</td>
</tr>
<tr>
<td>Kenya, Nairobi</td>
<td>18.3</td>
</tr>
<tr>
<td>Armenia, Yerevan</td>
<td>10.7</td>
</tr>
<tr>
<td>Senegal, Dakar</td>
<td>10.2</td>
</tr>
<tr>
<td>Lithuania, Vilnius</td>
<td>9.7</td>
</tr>
<tr>
<td>Egypt, Cairo</td>
<td>6.8</td>
</tr>
<tr>
<td>Nepal, Katmandu</td>
<td>6.3</td>
</tr>
<tr>
<td>Bangladesh, Dhaka</td>
<td>5.3</td>
</tr>
<tr>
<td>Colombia, Medelin</td>
<td>3.8</td>
</tr>
<tr>
<td>Albania, Tirana</td>
<td>0.5</td>
</tr>
</tbody>
</table>

Sources: UNODC, responses to annual report questionnaire; progress reports of UNAIDS on the global AIDS response (various years); the former Reference Group to the United Nations on HIV and Injecting Drug Use; and national government reports.

### Availability of harm reduction services remains low

In many countries, the levels of service coverage for needle and syringe programmes, opioid substitution therapy and antiretroviral therapy remain low, as defined according to targets set by WHO, UNODC and UNAIDS (see figure 8).\(^\text{17}\) The proportion of countries reporting these services as either not available or at low levels of coverage are 47 per cent, 41 per cent and 22 per cent, respectively. Most of the countries reporting information on service coverage are in Europe where the levels of service coverage are relatively high. Outside Europe the level of access to these services is much lower.\(^\text{18}\)

A recent review\(^\text{19}\) of the global coverage of services for needle and syringe programmes, opioid substitution therapy and antiretroviral therapy shows that 91 countries include the provision of harm reduction programmes in

---


\(^\text{17}\) The WHO, UNODC, UNAIDS Technical Guide for Countries to Set Targets for Universal Access to HIV Prevention, Treatment and Care for Injecting Drug Users: 2012 Revision recommends a comprehensive package of nine interventions, aimed at reducing the risk of acquiring, and improving the treatment and care of HIV, hepatitis and tuberculosis in people who inject drugs, commonly referred to as a “harm reduction approach” to injecting drug use.


their national policies, but that at the global level, harm reduction responses related to unsafe injecting remain poor. Needle and syringe programmes were available in 90 countries in 2014 (out of the 158 countries where injecting drug use has been documented), an increase of five since 2012, although the nature of these programmes varies considerably. In many low- and middle-income countries, however, they do not provide an adequate coverage to be fully effective. Since 2012, there has been a scale-up of needle and syringe services in 29 countries, but in 13 others the provision of services has actually decreased. Opioid substitution therapy was available in 80 countries in 2014, an increase of two since 2012. In many countries, however, opioid substitution therapy programmes remain at levels below international minimum guidelines. Since 2012, 25 countries have seen a scale-up of opioid substitution therapy, but in five others services have declined.

Progress towards realizing the commitments made in the Political Declaration on HIV and AIDS

The Political Declaration on HIV and AIDS adopted by the General Assembly in its resolution 60/262 in 2011 included a commitment by Member States to work towards reducing the transmission of HIV among PWID by 50 per cent by 2015. Some progress towards realizing this commitment can be noted. Globally, new HIV infections among PWID have declined slightly (by around 10 per cent) from an estimated 110,000 (range: 97,000-123,000) in 2010 to 98,000 (range: 85,000-111,000) in 2013. Although the accumulated evidence collected over the past 30 years points to the effectiveness of harm reduction measures, the implementation of such programmes remains at very low levels of coverage in many regions of the world.

Globally, every other person who injects drugs is living with hepatitis C

Hepatitis C has the potential to pose serious health problems for those infected, with the possibility of liver failure, liver cancer and premature death. While an estimated 2.2 per cent of the global population are infected with hepatitis C, this proportion is 25 times higher among PWID, estimated at 52 per cent for 2013, or 6.3 million PWID worldwide. This joint UNODC/WHO/UNAIDS/World Bank estimate is based on information from 88 countries. Although new or updated information from 36 countries has been included, the global estimate is essentially unchanged from that presented in the World Drug Report 2014.

In some countries, the prevalence of hepatitis C among PWID is considerably higher, including in countries with large PWID populations (see figure 9). Of these 88 countries, the prevalence of hepatitis C among PWID is 60 per cent or higher in 29 countries (33 per cent), including in China, where there were an estimated 1.93 million PWID in 2012,70 per cent or higher in 29 countries (22 per cent), including the United States, where there were an estimated 1.52 million PWID in 2007,26 and 80 per cent or higher in 10 countries (11 per cent).

---

20 Political Declaration on HIV and AIDS: Intensifying Our Efforts to Eliminate HIV and AIDS (General Assembly resolution 65/277, annex).
CHAPTER I
Health impact of drug use

Being aware of one’s hepatitis C status is important for access to treatment and also in preventing transmission of the infection to others. As shown in a recent systematic review, a high proportion of PWID are unaware that they are living with hepatitis C and, among those known to be infected, there is a low uptake of antiviral treatment in many European countries. The study indicated that the level of undiagnosed infection of hepatitis C among PWID was high, with a median of 49 per cent (range: 24-76 per cent), while among PWID diagnosed with hepatitis C, the proportion that had started antiviral treatment was generally low, ranging from 1 to 19 per cent with a median of 9.5 per cent. The burden of disease from hepatitis C infection (such as liver disease and mortality), where assessed, was high and the authors of the study concluded that it would rise in the decade from 2014.

Drug-related deaths are predominantly related to opioid overdose

With regard to the most serious outcome that can result from illicit drug use, UNODC estimates that in 2013 there were 187,100 (range: 98,300-231,400) drug-related deaths worldwide, corresponding to a mortality rate of 40.8 (range: 21.5-50.5) drug-related deaths per million people aged 15-64.

Overdose is the primary cause of drug-related deaths worldwide and opioids (heroin and non-medical use of prescription opioids) are the main drug type implicated in these deaths. Drug overdoses, with opioids present in about three quarters of the cases, are estimated to account for 3.5 per cent of all deaths among Europeans aged 15-39.

In Europe, the highest drug-related mortality rates are found in the most northerly countries and territories with (in descending order of mortality rates and considering only countries and territories with a population aged 15-64 of 500,000 or greater) Estonia, Scotland, Finland, Sweden, Northern Ireland, the Russian Federation, Norway and Ireland all experiencing mortality rates of over 70 drug-related deaths per million of the population aged 15-64. In all of these countries, opioids were the drug type most frequently mentioned as the primary cause of death.

Contributing an estimated 23 per cent to the global number of drug-related deaths, North America experiences the highest drug-related mortality rate by far. Within the region, the United States reports one of the highest drug-related mortality rates worldwide at 4.6 times the global average and, with 40,239 drug-related deaths recorded in 2013, accounts for approximately one in five drug-related deaths globally. The high mortality rate in North America in part reflects better monitoring and reporting of drug-related deaths than in most other regions.

TABLE 4. Estimated number of drug-related deaths and drug-related mortality rates, 2013

<table>
<thead>
<tr>
<th>Region</th>
<th>Number of drug-related deaths</th>
<th>Mortality rate per million aged 15-64</th>
<th>Availability of mortality data (percentage of total population in region)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>best estimate</td>
<td>lower estimate</td>
<td>upper estimate</td>
</tr>
<tr>
<td>Africa</td>
<td>37,800</td>
<td>18,000</td>
<td>57,700</td>
</tr>
<tr>
<td>North America</td>
<td>43,300</td>
<td>43,300</td>
<td>43,300</td>
</tr>
<tr>
<td>Latin America and the Caribbean</td>
<td>6,000</td>
<td>4,900</td>
<td>10,900</td>
</tr>
<tr>
<td>Asia</td>
<td>81,100</td>
<td>13,600</td>
<td>100,700</td>
</tr>
<tr>
<td>Western and Central Europe</td>
<td>7,300</td>
<td>7,300</td>
<td>7,300</td>
</tr>
<tr>
<td>Eastern and South-Eastern Europe</td>
<td>9,500</td>
<td>9,500</td>
<td>9,500</td>
</tr>
<tr>
<td>Oceania</td>
<td>2,000</td>
<td>1,700</td>
<td>2,100</td>
</tr>
<tr>
<td>GLOBAL</td>
<td>187,100</td>
<td>98,300</td>
<td>231,400</td>
</tr>
</tbody>
</table>


Note: For further information, see the methodology section in the online version of this report.


28 The definition of drug-related deaths varies between Member States but includes some or all of the following: fatal drug overdoses; deaths due to HIV acquired through injecting drug use; suicide; and unintentional deaths and trauma due to illicit drug use.

Heroin-related overdoses show recent increases in the United States

Substantial increases have recently been reported in the number of heroin overdoses in the United States (see figure 12). Mortality rates have nearly tripled from 1.0 to 2.7 heroin overdose deaths per 100,000 of the population between 2010 and 2013; this reflects an increase in the number of heroin-related deaths from 3,036 to 8,527\(^{30}\) (see also section on opiates).

Non-fatal overdoses are a common experience among drug users

While there has been a focus on overdose fatalities, non-fatal overdose among illicit drug users remains fairly common yet relatively undocumented. A number of studies have been conducted to understand the extent, patterns, determinants and correlates of non-fatal overdose, especially among regular opioid users and those injecting drugs; these studies suggest that between 30 and 80 per cent of the study participants have experienced an overdose in their drug-using career, nearly half of whom had experienced multiple overdoses in recent months.\(^{32-35,36}\) While the absence of specific assistance is largely at play, it would seem that in some cases victims of such incidents may fear the consequences of revealing their illicit drug use or may lack confidence in the health-care system.\(^{37-38}\) A number of studies have estimated that 1 in 20 or 25 overdose cases are fatal, with a cumulative risk of death increasing with each successive overdose.\(^{39,40,41}\)

Non-fatal overdose remains of public health significance because of its related morbidity and serious consequences, including pulmonary oedema, bronchopneumonia, peripheral neuropathy, renal failure, cognitive impairment and traumatic injuries sustained during overdose.\(^{42-43}\) Repeated...

Deaths related to new psychoactive substances are on the rise in the United Kingdom of Great Britain and Northern Ireland

In the United Kingdom of Great Britain and Northern Ireland, there has been much recent media attention over deaths relating to the use of new psychoactive substances (NPS). Over the past few years in England and Wales, the number of drug-related deaths in which NPS or so-called “legal highs” (predominantly methcathinones such as mephedrone, which has been controlled as a Class B drug under the United Kingdom Misuse of Drugs Act 1971 since April 2010) have been mentioned on death certificates has continually increased, from nine deaths in 2007 to 60 deaths in 2013.\(^{31}\) There is very limited information available on the toxicology of NPS and the overdose risk from the use of these substances, alone or in combination with other drugs (including alcohol), is largely unknown.


overdoses also place the person at a greater risk of long-term physical and cognitive damage, while survivors of a non-fatal overdose have a higher risk of suffering further overdose and death.44

The risk of overdose varies depending on different factors.45 Overdoses are reported in users with longer opioid use or long-term injecting, who are older, who are more likely to have been treated for drug dependence and who have a higher level of dependence on the severity of dependence scale.46,47 Overdoses are associated with higher drug purity; higher frequency of use — almost daily use or binge use of drugs;48 and polydrug use, particularly the use of amphetamines, cocaine, alcohol or benzodiazepines in conjunction with opioids, especially while injecting. The role of polydrug use in opioid overdose, for instance with benzodiazepines, essentially reflects a pharmacological interaction in the form of an additive respiratory depressant effect.49

Temporary cessation of drug use following periods of drug detoxification, hospitalization, arrest or imprisonment leads to decreased drug tolerance. When drug use is reinitiated, there is an increased risk of overdose. Importantly, enrolment in opioid substitution therapy would seem to protect from non-fatal overdose: in a study among PWID conducted between 1996 and 2004 in Vancouver, Canada, it was the only variable that was shown to be inversely associated with non-fatal overdose.50 Similarly, social marginalization or homelessness, together with living with HIV, have also been associated with overdose episodes, though evidence of a causal association has not been established.51

**Overdose is preventable**

Despite the high prevalence of non-fatal overdoses and the associated morbidity, scant attention has been given internationally to overdose reduction interventions. Overdose-related deaths are preventable. Along with long-term opioid agonist (substitution) treatment, the availability and accessibility of naloxone is another important intervention in cases of overdose. Naloxone is an opioid antagonist that can immediately reverse the effects of opioid overdose.52 As many overdoses occur in the presence of the drug user’s family members or peers, empowering these people with the skills to administer naloxone can be a lifesaving intervention.

C. GENDER, DRUG USE AND HEALTH CONSEQUENCES

**Use of drugs, except tranquillizers, is more prevalent in men than in women**

Compared with drug use among men, overall drug use remains low among women. At the global level, men are three times more likely than women to use cannabis, cocaine or amphetamines. By contrast, women are more likely than men to misuse prescription drugs, particularly prescription opioids and tranquillizers.53,54 This mainly reflects differences in opportunities to use drugs due to the influence of the social or cultural environment rather than intrinsic gender vulnerability.55

A large body of evidence has shown that processes of drug-use initiation, social factors and characteristics related to substance use, biological responses and progression to the development of problems related to substance use vary considerably between men and women.56 Women with substance-use disorders tend to have a history of over-responsibility in their families of origin and have experienced more disruptions and report more interpersonal conflicts in the family than their male counterparts, particularly issues related to parenting and exposure to childhood and adult trauma. Women with substance-use disorders may come from families where one or more family members is also drug dependent and may have suffered victimization and injury. Many women identify relationship problems as a cause for their substance use. In addition, psychiatric co-morbidities, especially mood and anxiety disorders, are reported to be higher among

---

44 S. Darke and others, “Patterns of nonfatal heroin overdose over a 3-year period: findings from the Australian Treatment Outcome Study”, *Journal of Urban Health*, vol. 84, No. 2 (2007), pp. 283-291.
46 Darke, Ross and Hall, “Overdose among heroin users in Sydney” (see footnote 32).
47 Bergenstrom and others, “A cross-sectional study on prevalence of non-fatal drug overdose” (see footnote 34).
48 Bazazi and others, “High prevalence of non-fatal overdose among people who inject drugs in Malaysia” (see footnote 45).
52 See also UNODC, *World Drug Report 2014*.
women\textsuperscript{57,58} and these disorders typically predate the onset of substance-use problems.\textsuperscript{59}

Literature on gender differences published over the past three decades has shown that women typically begin using substances later than men and that substance use by women is strongly influenced by intimate partners who also use drugs.\textsuperscript{60} Women overall may be less likely than men to develop drug-use disorders and dependence. Nevertheless, once they have initiated substance use, women tend to increase their rate of consumption of alcohol, cannabis, opioids and cocaine more rapidly than men\textsuperscript{61} and may progress more quickly than men to the development of drug-use disorders and dependence.\textsuperscript{62,63} In the United States, for instance, males were reported to be 2.33 and 2.25 times more likely to have had drug-use disorders and drug dependence, respectively, than females in the previous year.\textsuperscript{64,65}

In most surveys among the general population, a greater misuse of prescription drugs is reported among women than among men, with the difference in the use of sedatives and tranquilizers being more marked than in the use of prescription opioids or painkillers. Thus, women are twice as likely as men to use tranquilizers, but both have roughly equal levels of use of prescription opioids. Survey data from South America, Western and Central Europe and North America indicate that, in comparison with the use of most illicit substances, the extent of the misuse of tranquilizers at all levels, whether lifetime, annual or current (past 30 days), remains at a higher level among women than among men: for example, the aggregated past-year misuse of tranquilizers by women in Western and Central Europe is nearly twice that of cannabis use, while the use of other substances such as amphetamine, cocaine and opioids remains at very low levels (see figure 11).

\textsuperscript{57} Ibid.
\textsuperscript{58} D. Stewart and others, “Similarities in outcomes for men and women after drug misuse treatment: Results from the National Treatment Outcome Research Study (NTORS)”, Drug and Alcohol Review, vol. 22, No. 1 (2003), pp. 35-41.
\textsuperscript{60} Ibid.
\textsuperscript{63} Grella, “From generic to gender-responsive treatment” (see footnote 54).

Research has shown that while many people experiment with drug use, not many will repeat the experience on more than a limited number of occasions and even fewer of them will continue into more regular drug use. This is illustrated by the sharp decline observed when comparing lifetime with annual and current (past month) drug use. In the case of the misuse of sedatives and tranquilizers, this rate of attrition seems to be much lower than for other substances. Data from general population surveys in Western and Central Europe show that more than a third of men and women who initiate the misuse of tranquilizers continue to be regular or current users, whereas 17 per cent of men and 10 per cent of women may continue to
be regular cannabis users. Considering the high prevalence of the misuse of tranquillizers among women, this remains a significant problem.

**Women who inject drugs are often more vulnerable to HIV than their male counterparts**

The available data on gender disaggregated HIV prevalence among PWID point to the existence of gender disparities that are quite large in some countries (see figure 13). Data reported to UNAIDS\(^6\) show that FWID experience a higher prevalence of HIV in many countries with large populations of PWID (over 120,000), including India, Italy, Malaysia, Mexico, the Russian Federation and Ukraine. Additionally, in some other countries with a high prevalence of HIV among PWID, such as Indonesia, Kenya, Mauritius and Thailand, the prevalence of HIV is also higher among FWID. Females constitute sizeable minorities of the PWID populations in many countries, where, for example, 33 per cent of PWID in Canada are female, while this figure is 30 per cent in the Russian Federation, 26 per cent in Ukraine, 20 per cent in China and

**FIG. 12.** Ratio of annual and past-month prevalence to lifetime prevalence of drug use among women in Western and Central Europe, 2013 (or latest year available)

**FIG. 13.** Prevalence of HIV among females who inject drugs compared with prevalence of HIV among males who inject drugs (latest year available)

Source: UNAIDS, progress reports on the global AIDS response.

Note: Each circle represents a country. The solid circles are those countries with large numbers (over 120,000) of people who inject drugs. Data were available for 61 countries across all global regions.
10 per cent in Malaysia.67,68 Furthermore, in many countries the prevalence of HIV among females in prison is higher than among male prisoners.69

A review of 117 studies from 14 countries with a high prevalence of HIV among PWID (greater than 20 per cent) found an overall higher prevalence of HIV among FWID compared with MWID, although the difference was quite modest.70 There was also a very wide variation across the studies. In all 10 studies with the largest differences in HIV prevalence between FWID and MWID, the original authors point to sexual transmission as the reason for the difference. Similarly, combined data for nine countries in Europe found an overall prevalence of HIV among FWID of 21.5 per cent compared with 13.6 per cent among MWID.71 Again the differences across the countries were marked. In countries in sub-Saharan Africa, where in the general population females are more affected by HIV than males, HIV among FWID is particularly high compared with MWID: in Kenya, although FWID were few in number, the HIV prevalence is almost three times higher (44.5 per cent) than among MWID (16.0 per cent);72 in the United Republic of Tanzania, HIV among FWID (66.7 per cent) is more than double that among MWID (29.9 per cent);73 in Senegal, HIV among FWID (21.1 per cent) is three times higher than among MWID (7.5 per cent);74 in South Africa, HIV among FWID (17 per cent) is slightly higher than among MWID (14 per cent);75 and in Nigeria HIV among FWID (21.0 per cent) is seven times higher than among MWID (3.1 per cent).76 By contrast, a review of 11 studies from five countries in Central Asia found no overall gender differences in the HIV prevalence among PWID, but again there was considerable variation among the studies.77

There have been multiple reasons proposed why FWID may be at greater risk of becoming infected with HIV than their male counterparts.78,79 Females are more likely to be stigmatized and marginalized by society and are more likely to hide their injecting drug-use behaviour. Unsafe injecting practices may be more common among females given the greater difficulty in accessing needle and syringe programmes or treatment for drug dependence and the lack of services tailored to women’s needs.80 Surveys have documented high rates of sex work among FWID (often to support their own, as well as their sexual partner’s, drug use), and of inconsistent condom use, as well as higher rates of sharing of needles and syringes than among FWID who are not involved in sex work.81,82,83 The combined risks of unsafe injecting and unprotected sex work substantially elevates the risks of acquiring HIV for females.

One common feature that emerges from the different reviews and is seen in the data from UNAIDS is that the gender differences observed in individual surveys show a very wide variability. This highlights that local context is very important in the implementation of prevention programmes that are targeted and gender sensitive to cater for the separate needs of males and females where these needs are different.

73 Anna Bowring and others, Assessment of Risk Practice and Infectious Disease among Drug Users in Temeke District, Dar es Salaam, Tanzania: A Rapid Assessment and Response, prepared for Médecins du Monde — France (Melbourne, Australia, Centre for Population Health, Burnet Institute, 2011).
74 Enquête de prévalence et de pratiques à risques d’infection à VIH, VHB, et VHC chez les usagers de drogues dans la région de Dakar (Senegal), Etude ANRS 1224, rapport final (Paris, Agence Nationale de Recherche sur le Sida et les hépatites virales (ANRS), février 2014).
Women are less likely than men to access drug treatment

The problems that women experience as a result of drug use may interfere in more areas of their life than in men’s. The severity of the medical consequences of substance use and psychiatric co-morbidities are also reportedly higher among women. However, a convergence of evidence suggests that women with substance use disorders are less likely, over their lifetime, to enter treatment than their male counterparts, as they are more likely to face barriers that affect their access and entry to drug treatment.84,85

Globally, one out of three drug users is a woman yet only one out of five drug users in treatment is a woman, although this ratio is higher in Europe and Oceania (mainly reflecting Australia) than elsewhere.86 A higher proportion of women is, however, reported in the case of treatment for the misuse of tranquillizers and prescription opioids than other substances. Approximately one third of those in treatment for the use of tranquillizers are women, compared with approximately 10 per cent in the case of cannabis. This is most likely a reflection of the comparatively higher prevalence of use of tranquillizers among women than among men.

Gender disparities in access to substance-use treatment have mainly been associated with the limited availability of services tailored to meet the specific needs of women in treatment. As there remains limited information about women with substance-use problems, there is still a general lack of appropriate evidence-based treatment models for women, especially in resource-constrained countries.86

Women encounter significant systemic, structural, social, cultural and personal barriers in accessing substance abuse treatment.87,88 At the structural level, the most significant obstacles include lack of child care and punitive attitudes to parenting and pregnant women with substance abuse problems. This makes women fear losing custody of their children or having to relinquish their children as a condition of treatment, and prevents them from seeking treat-

85 Tuchman, “Women and addiction” (see footnote 56).
86 Substance Abuse Treatment and Care for Women: Case Studies and Lessons Learned (United Nations publication, Sales No. E.04.XI.24).
88 United Kingdom, National Treatment Agency for Substance Misuse, "Women in drug treatment: what the latest figures reveal" (London, 2010).
ment in residential settings. Treatment programmes may also be located far from where women live and may have inflexible admission requirements and schedules that may not suit the needs of women. Moreover, women with children may still need to secure child care to participate in outpatient treatment programmes as they may not have enough money to pay for child-care costs, transportation or treatment itself. Although men may be referred for treatment by their family, an employer or the criminal justice system, treatment history among women is more associated with and triggered by other problems, such as a diagnosis of antisocial personality disorder, or sex work, and could be referred by the social services system, mental health facilities or self-initiated, rather than solely due to substance abuse.

In many societies, substance use both in general and among women is heavily stigmatized and cultural norms may make it difficult for women to acknowledge such a problem or leave their homes and families to undergo treatment. Since many women with substance-use problems also live with a partner or other family members with a substance-use problem, relationship issues and the role of substance use within the relationship remain central issues in women obtaining support to undergo treatment. A growing body of evidence suggests that drug treatment services that attend to social needs and other gender-specific needs as well as those of ethnic groups can contribute to engagement, retention in treatment and improved treatment outcomes.

D. DRUG USE PREVENTION

What works in drug use prevention?

Prevention of drug use is one of the key provisions of international drug control systems. Aimed at protecting the health of people from harm caused by the non-medical use of controlled substances while ensuring availability of the health of people from harm caused by the non-medical use of controlled substances while ensuring availability of the health of people from harm caused by the non-medical use of controlled substances while ensuring availability of the health of people from harm caused by the non-medical use of controlled substances while ensuring availability of the health of people from harm caused by the non-medical use of controlled substances while ensuring availability of the health of people from harm caused by the non-medical use of controlled substances while ensuring availability of the health of people from harm caused by the non-medical use of controlled substances while ensuring availability of the health of people from harm caused by the non-medical use of controlled substances while ensuring availability of the health of people from harm caused by the non-medical use of controlled substances while ensuring availability of the health of people from harm caused by the non-medical use of controlled substances while ensuring availability of the health of people from harm caused by the non-medical use of controlled substances while ensuring availability of

Compared with treatment for drug dependence, for example, the science behind drug use prevention started to develop only relatively recently. In 2013, UNODC published the International Standards on Drug Use Prevention, which summarize the scientific evidence on the effectiveness of drug use prevention efforts. Notwithstanding some notable gaps in the base of evidence, UNODC was able to identify a series of interventions and policies that are effective in preventing drug use, substance abuse and other risky behaviours. Building on the International Standards, including recent reviews of the evidence and relevant single studies, this section outlines the possibilities and opportunities for success in preventing drug use that reside in the implementation of evidence-based interventions.

In this section, general conclusions about the effectiveness of prevention programmes are drawn from reviews that summarise the results of numerous single studies. To demonstrate the potential impact of specific effective prevention interventions, the results of high-quality single efficacy studies are presented. The selection criteria were that the studies utilized research methods to eliminate alternative explanations of intervention effects (using intervention and control groups that were randomized) and had long-term follow-up of the intervention and control groups.

Basics of prevention

There is no single cause of drug use and addiction. Drug use should be seen as an unhealthy behaviour linked to the developmental process. Although most drug use starts in adolescence, at least half of adolescents never experiment with drugs and some 20 per cent of them report past-month use of cannabis. In this context, it is important to note that what occurs during adolescence very much depends on what happened earlier on in an individual’s development, during childhood and early adolescence. For this reason, as shown below, drug prevention efforts can and should be targeted at earlier ages than adolescence.

In addition, vulnerability to drug use is due to a variety of factors, whether stemming from the individual or from developmental contexts (see figure 15). The interplay between these factors ultimately either increases or attenuates an individual’s vulnerability to substance use. This is

90 Grella, “From generic to gender-responsive treatment” (see footnote 54).
91 See, for example, United Kingdom, “Women in drug treatment: what the latest figures reveal” (see footnote 88), and Tuchman, “Women and addiction” (see footnote 56).
92 Grella, “From generic to gender-responsive treatment” (see footnote 54).
93 See footnotes 54, 88 and 89.
94 Article 4, paragraph (c), and article 38, paragraph 1, of the Single Convention on Narcotic Drugs of 1961 and articles 5 and 20 of the Convention on Psychotropic Substances of 1971.
Drug use is a developmental, multi-causal process influenced by the interplay of many risk and protective factors from different developmental contexts. The more distinct the risk factor, the greater the likelihood of drug use. In contrast, protective factors buffer the impact of risk factors.

why there is no “silver bullet” remedy for prevention, although multi-causality allows for many starting points for preventive activity. Evidence of different prevention interventions in settings significant to the target group — family, school, workplace, community, media and leisure settings — are presented in this section. These contexts are embedded in the wider society, where cultural norms and drug policies may also facilitate or discourage drug use. Indeed, as factors that promote drug use (such as availability of the drug or poor parenting and neglect) are often beyond the control of the individual, prevention works best if it acts at both the individual level and on the developmental contexts within which individuals evolve.

Individuals and groups vary in their risk of developing drug use because of its multi-causal nature. Groups with a higher risk, such as children with a substance dependent parent, should be approached in a different manner to population groups in which the majority does not tend to use psychoactive substances, such as school pupils. Prevention programming takes this into account by providing strategies for the population at large (universal prevention), for groups that are particularly at risk (selective prevention) and for individuals that are particularly at risk (indicated prevention, which also includes individuals that might have started experimenting and are therefore at particular risk of progressing to disorders). The impact of an intervention or policy depends on its effectiveness and how well it reaches the target group.

In many individuals, drug use is often only one of a number of risky behaviours that share several vulnerability factors. For example, many of the risk factors linked to substance use are also linked to outcomes such as violence, dropping out of school and risky sexual behaviour. Drug prevention addressing these common risk factors is thus also effective in preventing other risk behaviours.98 Similarly, preventing other problem behaviour may yield positive results in preventing substance use.99

Although problem behaviour and drug use peak in adolescence,100,101 they can be linked to very different developmental pathways. If it starts at all, problem behaviour starts during adolescence in the majority of youths, who then grow out of it during early adulthood. In such cases, drug use can be seen in the context of an unhealthy means of coping with developmental tasks and pressures specific to adolescence. By contrast, for a minority problem behaviour starts early and, if not addressed, is highly likely to persist throughout their lifetime. Such individuals are often characterized by a difficult temperament and externalizing or internalizing behaviours during childhood. Their drug use, which often begins in early adolescence, may be perceived as an expression of yet another facet of unhealthy behaviour that will change its characteristics over their lifetime.

The same behaviour (drug use in adolescence) thus has different sources — an observation to be considered when planning a prevention intervention. Figure 16 depicts different developmental pathways of cannabis use among students in the United States,102 among whom a minority of early and persistent frequent users was identified (chronic users), whereas the majority only rarely or temporarily used cannabis or did not use cannabis at all. To test the differential perspective, researchers compared the early and chronic users to the remaining sample with regard to problems in other substance use (i.e. other than cannabis), problem behaviours and well-being. Chronic users were different in several ways, which supports the idea that they experience more (and ongoing) difficulties than other youths. In particular, during their high school years they achieved lower grades and had lower college aspirations, and had lower school attendance rates and worked more hours. Later, in early adulthood, they were less likely to be married, have children or have graduated from college, and were more likely to experience unemployment.

The developmental notion of drug use behaviour implies that prevention should incorporate not only drug-specific components, but also skills that help individuals to deal effectively with the challenges of each phase of life, such as relationship skills for adolescents or parenting skills for parents. In fact, drug prevention is aimed at supporting the safe and healthy development of children and youth, but may also include, when relevant, additional aspects specifically related to drugs around the age of drug use initiation.

Drug-specific prevention in younger population groups often targets tobacco and alcohol rather than other drugs. An understanding of drug use from a developmental perspective also explains why this kind of early prevention is a way to prevent substance use in young adulthood, including illicit drug use (such as cannabis or other drugs). First of all, epidemiological research indicates that one rarely finds a drug user without previous or concurrent use of tobacco or alcohol.103,104 Secondly, a large number

104 K. M. Keyes, S. S. Martin and D. S. Hasin, “Past 12-month and lifetime comorbidity and poly-drug use of ecstasy users among...
CHAPTER I
Drug use prevention

of studies have shown that the earlier the use of a specific substance is initiated, the more likely it is that substance use disorders related to the specific substance are developed. Cross-substance analyses are rare, but in a high-quality study, a younger age at first alcohol and nicotine use was directly relevant for later initiation of cannabis use.\(^{105}\) Thirdly, prevention effectiveness studies show that long-term preventive effects on use of cannabis, opioids, cocaine, “ecstasy”, methamphetamines, non-prescription medicine or LSD in young adulthood can be explained by the fact that the participants of the programme initiated any substance use less often or less intensively in adolescence.\(^{106,107}\) Figure 17 illustrates a simplified model of long-term effectiveness in which participants in a family programme stayed on a less progressive track of drug use.

Settings for drug prevention and specific approaches that work

Family

The family-oriented prevention approach targets the setting that is most influential on the development of children and adolescents in general. Similarly, long-term observational studies tell us how important parental behaviour and attitudes are with regard to drug use, from pregnancy to young adulthood.

Examples of effective drug prevention efforts show that they start by providing adequate support to future parents who are burdened by their own drug use disorder, other mental health conditions or a socioeconomically disadvantaged life situation. Pregnancy is experienced as a time of uncertainty, but is also seen as a potential turning point towards a healthier lifestyle. Thus, prevention can take advantage of this special situation and (a) offer help with the various issues that these vulnerable groups are concerned with, and (b) motivate them to change their drug use behaviour. Positive preventive outcomes have been observed among children whose mothers were treated for substance use disorder and received parenting training.

Sources: Behrendt and others, “The relevance of age at first alcohol and nicotine use for initiation of cannabis use” (2012); Spoth and others, “Universal intervention effects on substance use” (2009); and Spoth and others, “Replication RCT” (2014).
during pregnancy. Similarly, prenatal and infancy visits during which a trained nurse or social worker supports parents in need of help with health, housing, employment or legal issues, in addition to parenting challenges, have proved to be effective in improving the child’s behaviour when it reaches adolescence.

Training programmes focused on parenting skills are a powerful tool, not only for populations at risk but also in the general population. In these programmes all parents are encouraged to raise their children in a warm and responsive manner and to become involved in their children’s lives and learn how to communicate effectively with their children and enforce rules and limits. Drug-specific content in these programmes pertains to the parents’ own substance use and, depending on the child in question’s developmental stage, the expectations the parents have about the child’s substance use and how to communicate about drug issues. Such interventions achieve positive preventive outcomes in the short and long run with regard to drug use and other problem behaviour.

Family programmes go one step further, by adding a child and family component to the parenting training. While parents are working on parenting skills, their children or adolescents learn how to improve their social and resistance skills, coping strategies, problem solving and decision-making. Specific to drugs, perceptions of the risks associated with use of drugs and social norms and attitudes towards drugs are discussed. Unique to this type of intervention is a subsequent family session, during which families are asked to communicate about controversial issues or resolve typical conflicts while organizing family leisure time. Family bonding activities are also part of the session. These programmes are expected to significantly lower the chance of initiating alcohol use (by roughly 30 per cent) and to reduce the frequency of alcohol use among participating adolescents. Rare long-term studies reveal that four years after the start of an intervention, participants had a 25 per cent less chance of alcohol use than if they had not participated in the family programme. With regard to other drugs, one programme produced an effect on the methamphetamine use of students in the twelfth grade. Although intervention effects are valid for girls and boys, as figure 18 indicates, the benefits appear to be even longer lasting for girls.


112 Ibid.


These interventions may appear to require considerable resources in their implementation, yet they are worthwhile according to cost-effectiveness estimations in the United States. Moreover, less intensive family-oriented efforts have also been shown to initiate preventive changes, though on a smaller scale. Such efforts should actively involve parents as much as possible and include developmental as well as drug-specific topics.

School and education

In drug prevention, the school setting serves as an access path for measures promoting knowledge and personal and social skills of individuals to attenuate individual risk factors of drug use (see figure 15). However, targeting the school system itself also has preventive potential, if it succeeds in promoting school bonding as well as drug-free norms.

Pre-school development programmes not only improve cognitive skills and school readiness among children from underprivileged backgrounds, they also have an impact on tobacco and cannabis consumption during later adolescent years. Reducing cannabis consumption by between 7 and 23 per cent has been achieved when providing these kinds of interventions to children at risk in kindergarten or pre-school programmes. Figure 19 illustrates the results of a study in the United States, in which, at age 21, the rate of current cannabis use was lower among young adults who had participated in a pre-school development programme than among a group of young adults who had a similar childhood but were not involved in the programme.

At elementary school children benefit from a series of sessions during which they learn and practise a wide range of personal and social skills to improve mental and emotional well-being, as well as to help them cope with difficult situations. Due to the young age of this non-using, universal population, drugs are not yet mentioned, although preventive effects can be observed on aggressive behaviour and early smoking initiation, which are important predictors of later drug use. Participation in personal and social skills training during elementary school leads to a significant reduction in both these dimensions of childhood problem behaviour compared with students in the control group.

Similarly, programmes that focus on improving the classroom environment yield positive drug-specific preventive outcomes, even if the primary focus is on academic and socio-emotional learning as well as addressing misbehaviour. Teachers are required to implement non-instructional classroom procedures in daily practices with all students, who in turn are rewarded for appropriate classroom behaviour. Figure 21 illustrates that among young male adults from the United States the probability of substance-related disorders in early adulthood was significantly reduced by participation in a classroom behaviour management programme in first grade, particularly if they behaved aggressively at that time. There was no such effect in the case of females.

Psychosocial life-skills education in early and middle adolescence is a prevention approach for a wide range of problem behaviours initiated in adolescence, including drug

115 T. Miller and D. Hendrie, Substance Abuse Prevention Dollars and Cents: A Cost-Benefit Analysis, DHHS publication No. (SMA) 07-4298 (Rockville, Maryland, Center for Substance Abuse Prevention, Substance Abuse and Mental Health Services Administration, 2008).

116 Petrie, Bunn and Byrne, “Parenting programmes for preventing tobacco, alcohol or drugs misuse in children <18” (see footnote 110).


120 Spoth, Greenberg and Turrisi, "Preventive interventions addressing underage drinking" (see footnote 109).


Most programmes include interactive exercises to improve several personal or social skills, such as self-awareness, creative thinking, relationship skills, problem solving, decision-making and coping with stress and emotions. Specifically with regard to substances, awareness of social influences on drug use is enhanced through critical thinking exercises. Creative thinking is used to identify functional alternatives to drug use and communication skills are built so as to increase assertiveness in resisting offers of drugs. Drug information focuses on short-term negative consequences and on normative education (that is, addressing the often exaggerated perception that adolescents have with regard to prevalence of drug use among their peers). Analysis combining the results of studies (meta-analysis calculations) on the effects of school-based illicit drug use prevention programmes estimated 28 per cent less cannabis use as a result of prevention programmes. Greater effects were obtained when programmes targeted adolescents aged 14 or older, included elements from various prevention models incorporating social learning, information and value-clarification, used


126 Foxcroft and Tsertsvadze, “Universal School-Based Prevention Programs for Alcohol Misuse in Young People” (see footnote 122).

127 Porath-Waller, Basley and Beirnes, “A meta-analytic review of school-based prevention for cannabis use” (see footnote 125).
interactive methods, had more sessions, were of longer duration and were mediated by persons other than teachers. The life-skills approach also serves as an effective drug prevention tool for older adolescents with higher vulnerability for substance use, such as students who are considered at-risk of not graduating at the normal pace.\textsuperscript{128}

These results corroborate the qualitative conclusion of a systematic review suggesting that “programs which develop individual social skills are the most effective form of school-level intervention for the prevention of early drug use” (cannabis and other drug use).\textsuperscript{129} In contrast, presenting children with fear-arousing information is ineffective in this particular age group, as is focusing only on building self-esteem or emotional education.\textsuperscript{130} It has been estimated that if adolescents aged 10 to 15 years receive a comprehensive programme, per month they drink alcohol on 12 days less and use cannabis on 7 days less than if they receive drug information only.\textsuperscript{131} Figure 22 illustrates how a comprehensive positive development programme shaped illegal drug use among participants in Hong Kong, China.\textsuperscript{132}

Computer-based universal prevention programmes without any teacher involvement have also been implemented in the school setting and have yielded effects in terms of less smoking and less alcohol use among participants.\textsuperscript{133} Fully automated software leads students through a series of sessions in which they identify social influences and are animated to correct their false perceptions of social norms. Internet-based programmes of this kind may work outside the school context as well, but reaching the target group may be a challenge.

In a study in the United Kingdom, middle-school students with an elevated risk level due to certain personality factors benefited from personal and social skills training tailored to the specific developmental challenges caused by their behavioural tendencies.\textsuperscript{134} Figure 23 shows how substance use developed for ninth graders with elevated scores in anxiety sensitivity, hopelessness, impulsivity and sensation seeking and therefore with elevated risk for drug use, depending on whether they were offered a tailored intervention or not. The two-session programme included goal-setting exercises, education about coping strategies typical for those personality traits and healthy alternatives, behavioural management and changing dysfunctional beliefs that often accompany such traits. Although alcohol and drug use were only a minor focus of the intervention, problem drinking was less probable among participants after the intervention.

Apart from implementing individual-oriented interventions, preventive effects can also be achieved by targeting the general climate and drug-specific rules of schools. Feeling left out motivates people to act against conventional norms. As a major socializing agent, the school system has the potential to integrate marginalized students and facilitate positive development. With children at risk, school-bonding activities to improve school attendance and attachment to school, in addition to promoting learning of age-appropriate language and numeracy skills, may have a positive influence in terms of developing important protective factors for students in middle childhood.\textsuperscript{135,136} Overall, interventions that promote a positive school ethos and enhance student participation and commitment to school, conjointly with rules that strongly discourage drug use among adolescents who participated in a school-based positive youth development programme at age 12.

\textsuperscript{128} Spoth, Greenberg and Turrisi, “Preventive interventions addressing underage drinking” (see footnote 109).
\textsuperscript{129} Faggiano and others, “School-based prevention for illicit drugs use: a systematic review” (see footnote 124).
\textsuperscript{130} Ibid.
\textsuperscript{133} K. E. Champion and others, “A systematic review of school-based alcohol and other drug prevention programs facilitated by computers or the Internet”, Drug and Alcohol Review, vol. 32, No. 2 (2012), pp. 115-123.
\textsuperscript{135} P. Lucas and others, “Financial benefits for child health and well-being in low income or socially disadvantaged families in developed world countries”, Cochrane Database of Systematic Reviews, No. 2 (2008).
\textsuperscript{136} A. Petrozino and others, Interventions in Developing Nations for Improving Primary and Secondary School Enrollment of Children: A Systematic Review, Campbell Systematic Reviews, No. 19 (2012).
use, may be an effective complement to drug prevention interventions addressing individual knowledge, attitudes and skills. The few existing studies show that this seems to work, especially for boys and for early adolescents.\textsuperscript{137,138} The consistent implementation of jointly developed behavioural standards with regard to drug use for all groups involved in school life, shapes social norms among students. By contrast, there is no evidence of preventive effects from random drug-testing at schools.\textsuperscript{139,140} A significant number of young adults (the age group with the highest drug use rates in high income countries) can be reached in tertiary education settings. Moving away from home to college is often paralleled by increased substance use (see figure 15). Alcohol prevention measures, which are effective with this at-risk group of young people, are brief interventions. These interventions encourage a person to document and reflect on his or her own consumption patterns and provide feedback on the person’s status relative to use of substances by peers. Brief interventions are effective when they are implemented in a face-to-face or computer-assisted format, as well as in individual or group formats.\textsuperscript{141,142,143,144} Interventions that challenge expectations of alcohol use are effective, especially with gender-homogeneous groups of college students.\textsuperscript{145}

**Workplace**

Prevention programmes in the workplace typically have multiple components, including drug prevention elements and policies, as well as counselling and referral to treatment. Rigorous prevention effectiveness studies are rare in this setting; some have assessed individual interventions but none have evaluated comprehensive approaches aimed at changing the entire system.\textsuperscript{146} Evidence from single studies is available with regard to alcohol use and suggests that alcohol education and stress management interventions, as well as personal or computer-based brief interventions, affect alcohol use or alcohol-related problems among employees. Availability of alcohol in the workplace is associated with alcohol use, so restricting access to alcohol and setting strict and unambiguous alcohol policies may prevent the drinking of alcohol before going to work, on the job and during breaks.

**Community**

The community can provide a preventive developmental context by setting clear standards with regard to the use of drugs, along with providing opportunities for adolescents to learn skills and to contribute to community life and be recognized for their contribution. Opportunities, skills and recognition strengthen bonding with family, school and community. Tight bonds motivate young people to adopt healthy standards of behaviour.

**Community-wide interventions for the general population**

Preventive effects were evidenced in programmes that incorporate multiple components in the community, especially when relating to alcohol but less consistently when


\textsuperscript{139} A. M. Roche and others, “Drug testing in Australian schools: policy implications and considerations of punitive, deterrence and/or prevention measures”, International Journal of Drug Policy, vol. 20, No. 6 (2009), pp. 521-528.


\textsuperscript{141} J. M. Cronce and M. E. Larimer, “Individual-focused approaches to the prevention of college student drinking”, Alcohol Research and Health, vol. 34, No. 2 (2011), pp. 210-221.

\textsuperscript{142} M. T. Moreira, L. A. Smith and D. Foscroft, “Social norms interventions to reduce alcohol misuse in university or college students”, Cochrane Database of Systematic Reviews, No. 3 (2009).


relating to tobacco and cannabis use.147,148,149 The minimum set-up is a combined approach of a school and a family intervention embedded in the structure of an organized community coalition. The coalition decides which evidence-based programmes to implement in the community. Some programmes do this on the basis of assessing a need that has been indicated by a student survey on risk and protective factors.

A universal community prevention model that originated in the United States and has since become international, supports and trains local coalitions of stakeholders to select and implement evidence-based prevention programmes targeting community-specific elevated risks for problem behaviours among adolescents. Six and a half years after the project had begun, youths exposed to this community initiative were 31 per cent less likely to have ever used alcohol, cigarettes or cannabis.150

Figure 24 indicates that cannabis use expands less and later during adolescence in university-school-community partnership districts in the United States. These districts provide a family programme in the sixth grade (13 to 14 year-olds) and a life skills, social influence or normative school programme in the seventh grade (14 to 15 year-olds) delivered in the framework of a university-community-school partnership.151 Figure 25 shows the difference in methamphetamine use in twelfth graders aged 19 to 20 years depending on whether they were involved in both the family and the school programmes or only in the school programme within the community partnership, or were in a school district that was part of the control group.

147 Foxcroft and Tsertsvadze, “Universal School-Based Prevention Programs for Alcohol Misuse in Young People” (see footnote 122).
151 R. Spoth, and others, “PROSPER community-university partnership delivery system effects on substance misuse through 6 1/2 years past baseline from a cluster randomized controlled intervention trial”, Preventive Medicine, vol. 56, Nos. 3 and 4 (2013), pp. 190-196.
Multi-sectorial interventions for vulnerable populations

Family-school approaches without a community component that are specifically designed for children at risk are also effective. The most prominent individual predictor of later substance use disorders in childhood is disruptive behaviour facilitated, inter alia, by poor impulse- and self-control and aggressiveness (see figure 26). From a developmental point of view, these characteristics hamper rewarding situations and relationships at school, in the family and with friends, and thus elevate the risk of alienation from conventional contexts. Alienated adolescents may have a tendency to turn to peers with deviant norms, which then facilitates maladaptive behaviour, including drug use. Therefore, targeting externalization of problems or disorders during childhood represents an important strategy for prevention not only of drug use but also of disruptive, antisocial and delinquent behaviours, as well as for addressing problems related to academic performance and dropping out of school. These training programmes or treatments allow parental or even familial involvement to be effective. Figure 26 shows the effect of social skills training at school with boys aged 7 to 9 years that was combined with parenting training during family visits in late adolescence. Further results of the study suggest that participants reported less drug use because of the programme’s support in lessening their impulsivity and antisocial behaviour and promoting making friends with less deviant peers. In addition, increased parental supervision contributed to the preventive effect of the programme.

Alcohol and tobacco policies

As mentioned in the preceding sections, a younger age at first alcohol and nicotine use was related with later initiation of cannabis use; thus, the prevention of alcohol and tobacco use is also relevant to the prevention of drug use. In this context, policies that increase prices (and thus manipulate affordability) and restrict access to these substances have been found to be very effective. From a tobacco price increase of 10 per cent, a reduction of 4 per cent in tobacco consumption can be expected.152 Similarly, a 10 per cent price increase is estimated to decrease heavy alcohol consumption by 5 per cent among older adolescents and even decrease binge drinking among young adults by between 9 and 35 per cent.153 In addition, study results in the United States consistently show that raising the minimum legal drinking age and enforcing its regulation reduces alcohol consumption and alcohol-related accidents while lowering the legal drinking age increases use and related problems.154

Leisure, sports and entertainment venues

Unlike school and family settings, recommendations for interventions in other areas of community life cannot be made based on the same level of evidence. The effectiveness of specific drug prevention efforts in leisure settings, for example peer education programmes at festivals or activities in sports clubs, has not yet been studied in depth. This may be surprising as peer education programmes are widely used in drug prevention and other prevention domains.155 Sports clubs have been described as both a setting with great potential for promoting good health and a risk environment for drug use,156 but effectiveness studies are not available. Furthermore, providing low-resource-intensive leisure activities to children and youths is a popular non-drug-specific prevention intervention, but these activities have not been empirically studied with regard to their effect in attenuating substance use or risk factors of substance use. Theoretically, they may in fact constitute an element of a healthy developmental context. Nevertheless, whether they yield drug use preventive effects remains unknown. Research on the effectiveness of

---


---

**FIG. 26.** Differences in drug use among vulnerable boys who participated in a skills training programme for students and their parents

![Graph showing differences in drug use between Parenting/school intervention at age 7-9 and Control](image_url)

after-school programmes that aim to promote personal and social skills points to the fact that risky behaviours in general, including drug use, can be prevented but only under certain conditions, that is, if they use a connected and coordinated set of activities, as well as interactive methods, have at least one component devoted to developing personal or social skills and explicitly target the skill in question.\textsuperscript{157} In this scenario, after-school programmes are more of a setting to deliver life skills education than a separate programme.

Mentoring programmes are another approach among after-school programmes. Lay adults spend structured leisure time with a child or adolescent on a weekly basis. With adolescents at average risk, modest preventive effects were observed for general risk behaviour, including drug use.\textsuperscript{158} Mentoring programmes for groups with a high proportion of minority and underprivileged adolescents can be expected to reduce the risk of alcohol use initiation among the mentees by 29 per cent, whereas effects on other drug use are rare.\textsuperscript{159}

Most prevention programmes utilizing entertainment venues have multiple components, including different combinations of training of staff and managers on responsible beverage service and management of intoxicated patrons; changes in laws and policies, for example with regard to serving alcohol to minors or to intoxicated persons or with regard to drinking and driving; high visibility enforcement of existing laws and policies; communication to raise awareness and acceptance of the programme and to change attitudes and norms; and offering treatment to managers and staff. Training of staff, policy interventions and enforcement may reduce intoxication.\textsuperscript{160,161} Although community support through training servers of beverages in nightlife settings or of vendors of cigarettes may succeed in educating commercial suppliers of alcohol and tobacco, preventive effects at the community level can only be expected to be successful if regulations are enforced, that is controlled and sanctioned.\textsuperscript{162,163,164}

**Health sector**

The community health sector can prevent progression to substance use disorders (when it is in touch with individuals already using drugs) by providing brief interventions. In the few, short and structured sessions of these interventions, trained health or social workers first identify whether there is a problem of substance use and then provide basic counselling or referral to additional treatment. Brief interventions work in many settings (school or medical or community-based treatment centres) if they target cannabis use and follow the motivational enhancement approach.\textsuperscript{165,166} It differs from other treatment interventions in that its purpose is not to impart information or skills; rather, it picks the client’s general and drug-specific goals as a central theme for promoting ambivalence and readiness to change while supporting the person’s autonomy. Figure 27 demonstrates the effectiveness of a brief motivational intervention after 12 months, conducted in the United States by peer educators during a visit to a paediatric emergency department, to negotiate abstinence or reductions in cannabis use and its related consequences among 14 to 21 year olds.\textsuperscript{167} Adolescents and young adults used cannabis less frequently if they received the brief motivational intervention.

![FIG. 27. Frequency of cannabis use by adolescents and young adults after receipt of a brief intervention in a paediatric emergency room](image)

Source: Bernstein and others, “Screening and brief intervention to reduce marijuana use among youth and young adults in a pediatric emergency department” (2009).

---


\textsuperscript{159} R. E. Thomas, D. Lorenzetti and W. Spragins, “Mentoring adolescents to prevent drug and alcohol use”, *Cochrane Database of Systematic Reviews*, No. 2 (2011).


\textsuperscript{162} Bolier and others, “Alcohol and drug prevention in nightlife settings” (see footnote 160).

\textsuperscript{163} Lindsay F. Stread and Tim Lancaster, “Interventions for preventing tobacco sales to minors”, *Cochrane Database of Systematic Reviews*, No. 1 (2005).

\textsuperscript{164} Joseph R. DiFranza, “Which interventions against the sale of tobacco to minors can be expected to reduce smoking?”, *Tobacco Control*, vol. 21, No. 4 (2012), pp. 436-442.

\textsuperscript{165} T. Carney and others, “Brief school-based interventions and behavioural outcomes for substance-using adolescents”, *Cochrane Database of Systematic Reviews*, No. 2 (2014).


\textsuperscript{167} E. Bernstein and others, “Screening and brief intervention to reduce marijuana use among youth and young adults in a pediatric emergency department”, *Academic Emergency Medicine*, vol. 16, No. 11 (2009), pp. 1174-1185.
Media

On a societal level, besides availability and affordability, norms favourable to drug use constitute a risk factor for drug use (see figure 15). As already described, affordability and availability may be influenced by enforcement of laws and regulations. Laws and regulations may also be understood as formal expressions of social norms. Children, adolescents and young adults face norms of drug use informally by means of approval or disapproval expressed by peers, parents, teachers, neighbours and other community members. Media campaigns are a way to influence these informal social norms. Awareness campaigns or expanding media coverage to increase awareness of and focus on drug-related issues are often one component of state or community programmes and there are positive indications regarding their effect on tobacco consumption. Nevertheless, campaigns cannot be expected to influence drug use behaviour directly. Although observational data suggest that methamphetamine deterrence campaigns in the United States are paralleled by a reduction in current drug use in the teenager cohort, these results are corroborated by rigorous studies. Anti-illicit-drug public-service announcements in traditional and new media demonstrated no significant effect on drug use in high quality effectiveness studies and may even be harmful by weakening anti-cannabis norms among young target groups.

The way forward

The scientific evidence reviewed and presented in this section illustrates that effective and feasible interventions and policies are available for drug prevention. However, the gaps in both evidence and effectiveness research point to the fact that more evaluation of impact is needed. Reaching those groups with heightened vulnerability remains a challenge, while the question of how to adapt interventions developed in optimal conditions to real-life, local contexts has not yet been fully answered.

Many activities labelled as drug prevention are not evidence-based, their coverage is limited and their quality unknown at best. Among other international organizations, UNODC has tried to fill this evidence gap through its International Standards on Drug Prevention, which clearly identify interventions and policies that work and the characteristics that are linked to positive prevention outcomes. In addition, the EMCDDA European Quality Standards of Drug Prevention provide support in how to implement quality interventions and other remarkable tools have also been developed.

In summary, countries need to move away from a model in which prevention of drug use is delivered by isolated but well-intentioned individuals who improvise in delivering interventions. Based on the specific situation, interventions should employ and expand the use of evidence-based tools systematically, supporting practitioners and policymakers in developing their knowledge, skills and competencies and building a critical mass of genuine prevention specialists capable of promoting the safe and healthy development of children, youth, families and communities through effective prevention of drug use.

E. TREATMENT OF DRUG USE

Treatment of drug use disorders and dependence

With an estimated global average of one in six people who suffer from drug-use disorders or drug dependence receiving treatment each year, it is clear that the accessibility and availability of services for such conditions are limited in most countries. The fact that this figure is approximately 1 in 18 in Africa, compared with 1 in 5 in Western and Central Europe, however, points to large disparities between regions. Not included in these figures is the large proportion of drug users who may not be dependent but may still require interventions to prevent an escalation in their disability and comorbidity related to drug use.

Disparities between regions also exist in the principal drugs for which drug users receive treatment, with cannabis being the principal drug reported in Africa, cannabis, cocaine and to a lesser extent opioids in North America, and cocaine and cannabis in Latin America. In Asia, opioids remain the principal drug type for which drug users receive treatment, followed by ATS and cannabis. In Europe, opioids are followed by cannabis, cocaine and ATS, while in Oceania cannabis is followed by opioids and ATS. It should be noted, however, that while treatment demand highlights the main substances of concern, it also reflects the nature of available drug treatment services.

Although regional differences in the availability of different interventions exist, psychosocial interventions, particularly counselling and social assistance services, are more readily accessible and available globally than other interventions. Indeed, more than a third of countries reported the availability of psychosocial, rehabilitation and aftercare services whereas less than a quarter reported the availability of pharmacological interventions (see figures 28-30).

171 Based on the responses to the annual report questionnaire on availability and coverage of drug treatment services. See also E/CN.7/2015/5.
It is difficult to determine the quality of different types of intervention available at the global level, but there is a greater level of pharmacological and psychosocial services and interventions in Europe than in other regions, particularly Western and Central Europe, where higher levels of opioid substitution also reflect the fact that opioids are the major substance for which drug users receive treatment in the region. In other regions, Governments may not yet be ready to address drug dependence with pharmacologically assisted treatment, leading to limited coverage of such programmes.

In Africa, the fact that counselling is more available than other types of intervention could be due to cannabis being the most common substance for which drug users receive treatment. However, most drug treatment services in the region are provided in specialized psychiatric hospitals, which may explain why there is a considerable number of interventions in the treatment of psychiatric comorbidities in Africa, although the lack of other types of intervention in Africa may also indicate limited responses to treatment needs in general.

Not only are available services for the treatment of drug use disorders and dependence limited in most countries, there is an overall lack of provision of a continuum of care in interventions to address drug use disorders and drug dependence adequately among those in need of these inter-

---

**FIG. 28.** Global extent of drug dependence treatment services, by region

**Pharmacological treatment**

<table>
<thead>
<tr>
<th>Number of Member States</th>
<th>Detoxification</th>
<th>Opioid substitution therapy</th>
<th>Opioid agonist treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>low</td>
<td>4</td>
<td>8</td>
<td>2</td>
</tr>
<tr>
<td>medium</td>
<td>6</td>
<td>10</td>
<td>3</td>
</tr>
<tr>
<td>high</td>
<td>8</td>
<td>12</td>
<td>5</td>
</tr>
</tbody>
</table>

Source: Annual report questionnaire, part II (Member State responses on treatment of drug dependence in 2013).

**FIG. 29.** Global extent of drug dependence treatment services, by region

**Psychosocial treatment**

<table>
<thead>
<tr>
<th>Number of Member States</th>
<th>Screening and brief interventions</th>
<th>Treatment planning</th>
<th>Counselling</th>
<th>Cognitive behavioural therapy</th>
<th>Motivational interviewing</th>
<th>Contingency management</th>
<th>Peer support groups</th>
</tr>
</thead>
<tbody>
<tr>
<td>low</td>
<td>2</td>
<td>5</td>
<td>10</td>
<td>3</td>
<td>5</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>medium</td>
<td>5</td>
<td>10</td>
<td>20</td>
<td>7</td>
<td>10</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>high</td>
<td>10</td>
<td>20</td>
<td>25</td>
<td>15</td>
<td>20</td>
<td>10</td>
<td>10</td>
</tr>
</tbody>
</table>

Source: Annual report questionnaire, part II (Member State responses on treatment of drug dependence in 2013).
ventions. An outline of what drug treatment actually entails, particularly when considered a chronic condition, and how it should be measured for effectiveness is provided in this section.

Philosophy of chronic care versus acute care: continuity of interventions

Scientific evidence indicates that the development of drug use disorders and dependence is a result of a complex multi-factorial interaction between repeated exposure to drugs and biological and environmental factors. In recent decades, important advances have been made in understanding drug dependence as a complex, multifaceted and relapsing chronic condition. Such a condition therefore requires continuing care and interventions from many disciplines.

These findings have led to increased interest in the development of effective prevention and treatment strategies. It is now known that drug use disorder is a preventable and treatable health problem, and effective, comprehensive and multidisciplinary interventions are available to respond to the different needs of affected individuals.

There are fundamental differences in the philosophies relating to the treatment of acute and chronic conditions. Acute conditions such as bacterial infections, appendicitis and broken bones, tend to have a clearly identifiable cause (for example an infectious agent, physical trauma, etc.) and can be treated in a relatively short period of time. The symptoms of acute disorders may be intense and disruptive, but people who are treated generally recover with no lasting deterioration of functional capabilities. An individual may break another bone or get another infection, but this is considered a new occurrence, not a relapse. Treatment services for acute disorders are typically delivered in a series of isolated activities — screening, admission, single point-in-time assessment, treatment procedures, discharge and brief “aftercare” followed by the termination of the service relationship. The individual, family or community is given the impression at discharge that “cure has occurred”, which is often the case. Long-term recovery is then self-sustainable without ongoing professional assistance.

By contrast, chronic health problems such as diabetes, asthma and hypertension are influenced by multiple biological, psychological and social factors, some of which cannot be clearly identified. Lifestyle or personal behavioural choices are often intimately involved in the onset and course of these disorders. There are many effective treatments for chronic disorders, but they tend to be more complex and protracted than acute treatments and do not

174 Ibid.
often result in a “cure” or the same outcome as the treatment of acute conditions. Yet multiple treatment interventions for chronic conditions have been found to be very effective. Treatment of these chronic conditions share three important features:

(a) They can usually remove or reduce symptoms without necessarily removing the root causes of a disease. For example, beta blockers reduce blood pressure and insulin improves the body’s ability to digest sugars, as long as the affected individual continues the treatment, i.e., continues taking the medicine;

(b) Treatment of all chronic conditions requires significant changes in behaviour and lifestyle on the part of the patient in order to maximize their benefit. Again, even if individuals with diabetes regularly take their insulin as prescribed, the disease progression will continue if they do not also reduce their intake of sugar and increase physical exercise;

(c) Because of the complexity of the factors that can lead to a chronic illness and the need for ongoing medical care and lifestyle change, it is not surprising that relapses are very likely to occur in all chronic illnesses.

For these reasons, most contemporary treatment strategies in chronic illness involve regular monitoring of medical adherence, coupled with encouragement and support for pro-health behavioural changes as well as support by trained family members, to provide continuing monitoring and assistance for the behavioural changes necessary to sustain good quality of life. Consequently, “nothing less” must be provided or can be effective for the treatment of drug dependence than a qualified, systematic, science-based approach, similar to treatment of other chronic health problems such as diabetes or hypertension.

Is drug treatment better than no treatment?

Effectiveness of treatment

For over four decades scientific research has shown that effective treatment for drug-use disorders has helped drug-dependent individuals to halt their consumption, prevent relapse, reduce their involvement in crime, change other dysfunctional behaviour and make a positive contribution to their family and community. Effective treatment typically incorporates many components — pharmacotherapy, behavioural therapy and social support — each directed towards a particular aspect of the disorder and matching an individual’s particular problems and needs.

Treatment programmes for women

Research indicates that current addiction treatment programmes can be effective for different age and gender groups. Studies that have reviewed treatment programmes for women indicate that women who are enrolled in gender-specific programmes, which in addition to pharmacotherapy and behavioural therapy address their unique treatment needs, have better treatment outcomes and improvements in important areas of their lives than those women who are in non-gender-specific programmes. These interventions may include addressing psychosocial issues that are more prevalent among women such as child care and employment support, family issues, psychiatric comorbidities, and psychological issues such as child abuse and trauma, victimization.

Treatment programmes for adolescents

The findings of several large studies clearly indicate that treatment programmes can decrease drug and alcohol use, improve school performance and reduce the nature and extent of problem behaviours. The National Institute on Drug Abuse supported Drug Abuse Treatment Outcome Studies for Adolescents (DATOS-A) reviewed 23 community-based adolescent treatment programmes, which in essence addressed peer relationships, educational concerns and family issues such as parent-child relationships and parental substance use. They also included elements of adult treatment programmes, such as participation in group therapy and in a 12-step programme. Adolescents who participated in these treatment programmes have reported improved psychological adjustment, and longer stays in treatment produced more favourable outcomes in several of the criteria. However, strategies specific to adolescents are needed to improve their treatment retention and completion in order to maximize the therapeutic benefits of drug treatment.

Cost and benefit of treatment

An apparent major benefit of drug treatment, aside from the recovery of the patient and the subsequent health and social implications, is the element of cost, as research studies indicate that spending on treatment is cost-

181 Ibid.
182 Ibid.
188 Ibid.
effective.\textsuperscript{189,190,191} At least, the ratio of saving to investment is 3:1 (for every dollar invested three are saved), and when a broader calculation of costs associated with crime, health and social productivity is taken into account, the rate of savings to investment can rise to 13:1.\textsuperscript{192}

When the cost of each option is weighed up, it can be shown that drug treatment is less expensive than either incarceration or a complete lack of treatment.\textsuperscript{193} Drug treatment is cost-effective in reducing drug use along with its associated health and social costs and it is also less expensive than the alternatives, such as not treating addicts or simply incarcerating dependent users. For example, in the United States the average cost of one full year of methadone maintenance treatment is approximately $4,700 per patient, whereas one full year of imprisonment costs approximately $18,400 per person.\textsuperscript{194} In the United Kingdom, it is estimated that, with under 165,000 people in treatment for heroin and/or “crack” dependency, an estimated 4.9 million acquisitive crimes such as burglary, robbery and shoplifting were prevented during 2010-2011.\textsuperscript{195}

Although many treatment activities can be initially resource intensive, every dollar invested in treatment yields up to 10 dollars in reduced costs in lost productivity, use of social services and criminality.\textsuperscript{196} When savings related to health care are included, total savings can exceed costs by a ratio of 12 to 1. Major savings to the individual and society also come from significant drops in interpersonal conflicts, improvements in workplace productivity and reductions in drug-related accidents.

**Why drug treatment is often perceived to be ineffective**

The scientific evidence is clear that the best available treatments for individuals with drug dependence are those that are ongoing, able to address multiple problems in numerous life domains — such as medical and psychiatric symptoms and social instability — and are well integrated into the community, making them available and accessible to such individuals.

One major difference in the perception of their ineffectiveness is that drug dependence treatments are not provided and evaluated under the same assumptions that pertain to other chronic illnesses. Particularly important in this regard is that drug dependence treatments are rarely delivered under a continuing care model that would be appropriate for a chronic health problem. Indeed, with the exception of methadone maintenance and the 12-step approach, most contemporary treatments for drug dependence are acute care episodes.

It is common for a drug dependent individual to be admitted to a 30 to 90 day outpatient rehabilitation programme,\textsuperscript{197} rarely accompanied by medical monitoring or medication. This period of treatment is typically followed by discharge and while the intentions and overall goals of treatment might be conceptualized as ongoing by those in the treatment field, operationally addiction treatments are delivered in much the same way as one might treat a patient with a broken bone or with an acute infection.

Outcome evaluations tend to be conducted 6 to 12 months after treatment discharge. A major (and sometimes exclusive) measure in all such evaluations is whether patients have been continuously abstinent since leaving treatment. In other words, policymakers and society in general generally ignore the fact that during treatment patients are most likely to experience significant symptom (compulsive drug use) decrease and an improvement in psychosocial functioning, with treatment effectiveness only being measured based on pre- and post-outcomes, an approach that is applicable for the treatment of acute conditions.

If these goals and this treatment/evaluation strategy were applied to a hypothetical hypertension treatment regime, patients who meet diagnostic criteria for hypertension would be admitted to a 30 to 90 day outpatient “hypertension rehabilitation” programme where they might receive medication, behavioural change therapy, dietary education and an exercise regime. Because of some ideological limits and evaluation goals, the medication would be tapered during the final days of the treatment and patients would be referred to “community sources”. The evaluation team would re-contact the patient six months later and determine whether the patient continuously had normal blood pressure throughout the post-treatment period. Only those patients who met this criterion would be considered “successfully treated”. Clearly, this hypothetical treatment management strategy and its associated


191 L. W. Gerson and others, “Medical care use by treated and untreated substance abusing medicad patients”, *Journal of Substance Abuse Treatment*, vol. 20, No. 2 (2001), pp. 115-120.


195 United Kingdom, National Health Services, National Treatment Agency for Substance Misuse, “Falling drug use: the impact of treatment”, December 2012.


197 McLellan and others, “Reconsidering the evaluation of addiction treatment” (see footnote 175).
outcome evaluation approach would be absurd if applied to any chronic illness, including drug dependence.

**How to measure success in treatment**

As discussed in the previous section, traditionally treatment of drug dependence has been seen in the context of acute care and a simple recovery/rehabilitation oriented model, which assumed relatively short interventions and services after which the patient is considered successfully treated, discharged and expected to continue their recovery.\(^{198}\) As noted by McLellan and colleagues,\(^{199}\) “Typically, the immediate goal of reducing alcohol and drug use is necessary but barely sufficient for the achievement of the longer-term goals of improved personal health and social function and reduced threats to public health and safety — i.e., recovery.” Moreover, as noted by the Betty Ford Institute Consensus Panel on “what is recovery”, unlike the term “cancer survivor”, for instance, the term “in recovery” has not been clearly defined and may not be well understood by the public.\(^{200}\)

Consequently, the traditional method of evaluating treatment outcomes has been to contact patients after certain intervals and assess if the person has retained those positive changes, including “cessation of drug use” following discharge. As research has shown, the majority of patients relapse following cessation of treatment, giving rise to the interpretation that available treatment of drug dependence is not effective.

As substance-use disorders are increasingly viewed as chronic conditions, drug dependence treatment services have also adopted models that aim to assess effectiveness of interventions and the impact of the health problem on the person’s overall well-being regularly over the course of treatment.

The different treatment outcome domains identified as relevant to both the patient and to society include:  

(a) Reduction in substance abuse; increase or improvement in personal health including physical and psychological improvements (including spiritual);  
(b) Improvement in social functioning, including employment, family and social relationships;  
(c) Reductions in behaviours that are a threat to public health and safety or that are associated with the spread of infectious diseases or with personal and property crimes.

It has therefore been suggested that outcome evaluations of addiction treatment should use clinical and social behavioural indicators with repeated measurement procedures commonly used in chronic medical conditions as part of standard treatment delivery.\(^{204}\)

**Treatment in primary health-care settings**

Drug use is one of the top 20 risk factors for poor health worldwide and among the top 10 in developed countries. Drug use disorders are associated with an increased risk of other diseases such as HIV/AIDS, hepatitis, tuberculosis and cardiovascular diseases, as well as suicide and overdose deaths. Injecting drug use is a major conduit of HIV and hepatitis transmission in many regions.\(^{205}\) Additionally, individuals with drug use disorders have health-care costs that are nearly twice as high as those of patients without such disorders, which contributes to the growing cost of health care.\(^{206}\)

Despite the availability of effective treatments, most individuals with drug use disorders have never been treated.\(^{207}\) A big gap exists between the number of people who want or could benefit from treatment for drug use disorders and the number of people who actually receive services.\(^{208}\)

There are many reasons for this, with one of the key factors being the difficulties in accessing treatment due to insufficient integration of substance use disorder services in mainstream general health-care delivery. This lack of integration is a problem because so many individuals who

---

198 Ibid.
199 Ibid.
201 McLellan and others, “Reconsidering the evaluation of addiction treatment” (see footnote 175).
204 McLellan and others, “Reconsidering the evaluation of addiction treatment” (see footnote 175).
206 C. Boyd and others, “Clarifying multimorbidity to improve targeting and delivery of clinical services for medicaid populations”, *Faces of Medicaid Data Series* (Hamilton, New Jersey, Center for Health Care Strategies, December 2010).
need drug treatment services also need other health services. This problem is particularly severe for vulnerable groups who have limited or no contacts with health-care providers.

However, the data show that individuals are seldom screened for drug-related problems by their primary-care physicians. The failure of providers to identify drug use issues is typically due to reluctance to deal with these illnesses, and remains one of the most common obstacles to early diagnosis and treatment. Contributing factors include inadequate medical training to deal with drug use disorders, a belief that there is no effective treatment, insufficient time during the visit and a general feeling of inadequacy.

Providing screening and initial services in primary healthcare settings is feasible, and it can reach many more individuals than can rely on specialized treatment alone, promises better outcomes for patients and can result in reduced overall health-care costs. Early detection of drug-related problems can facilitate treatment and, ultimately, a reduction in the significant disability and comorbidity that accompany these disorders. Therefore, it is critical for primary-care practitioners to recognize and effectively respond to patients with drug use issues.

The first step is screening and assessment that will enable the integration of clinical findings into a potential diagnosis of drug use disorders. The timing of the diagnosis is critical, since early intervention, before severe complications have happened and a patient’s relationship with the drug becomes stronger than relationships with family and friends, is the most effective. Once a diagnosis of drug use disorder has been established, an intervention can either be implemented by the primary health-care practitioner, or patients can be referred to the appropriate specialist for treatment. While a specialty treatment programme remains the gold standard, various studies demonstrate that a primary health-care role in early intervention is essential to the success of any treatment.

Targeted brief interventions can be effective primary-care treatment models, as demonstrated by studies on brief office-based interventions. Studies evaluating the effectiveness of integrating primary medical care with addiction treatment have demonstrated cost benefits and improved medical outcomes. For example, patients with primary-care connections were shown to be less likely to seek expensive emergency department and hospital services while for every dollar invested in evidence-based integrated treatment, up to six dollars are saved in terms of costs for health, security and welfare.

Efforts to integrate substance use disorder services with primary care face significant barriers, many of which arise at the policy level. Integrating drug treatment with mainstream primary health-care delivery, expanding and developing specific competencies in primary health-care practitioners, enabling same-day services, improving access to medications and improving access to specialty care should be the global priorities.

F. EXTENT OF DRUG SUPPLY

The regions in which the cultivation and manufacture of drugs take place have not changed. Herbal cannabis production occurs in most countries worldwide, while the production of cannabis resin remains confined to a few countries in North Africa, the Middle East and South-West Asia.
Asia. In South America, three Andean countries continue to account for virtually all global cultivation of coca bush, while the vast majority of illicit opium poppy cultivation worldwide remains concentrated in two countries in Asia. The manufacture of synthetic drugs is difficult to assess in a quantitative way, but there are reports of the manufacture of ATS in all regions. The emergence in recent years of a large number of NPS has increased the range of synthetic drugs available on the market, but it is difficult to ascertain whether these substances are replacing existing drugs under international control.

Cannabis continues to be the most-seized drug worldwide, both in terms of the number of seizure cases and actual quantities intercepted. This is probably due to the fact that the cannabis market is the largest drug market globally with an extremely extensive web of trafficking flows. With the exception of heroin/illicit morphine and ATS, overall quantities of drugs seized in the past decade have

---

**FIG. 31.** Global trends in main indicators of drug supply and drug supply reduction, 2005-2014

Source: UNODC, responses to annual report questionnaire and other official sources.

**FIG. 32.** Distribution of global seizures, by drug and region (number of cases), 2005-2008 and 2009-2013

Source: UNODC, responses to annual report questionnaire and other official sources.

**INTERPRETING DRUG SEIZURES**

A direct indicator of counter-narcotics law enforcement activity, drug seizures are the result of those successful operations that end in drug interceptions, and are thus influenced by law enforcement resources and priorities. At the same time, seizures are one of the key elements that help to establish the size of drug markets, drug availability and trafficking patterns and trends, particularly if broad geographical entities are considered and long periods are analysed. For example, the expansion of the cocaine market in Europe from the mid-1990s to the middle of the first decade of the 2000s was reflected in rising cocaine seizures. Similarly, the 2001 “heroin drought” in Australia and the sharp decline in the cocaine market in the United States from 2007 to 2012 were also reflected in falling seizures.

Seizure information can serve as a powerful market indicator, particularly if triangulated with other data such as drug prices and purity. Falling seizures in combination with rising drug prices and falling purity levels may suggest a decline in overall drug supply, while rising seizures in combination with falling drug prices and rising purity levels are usually considered a good indicator of an increase in drug supply. However, rising drug seizures in combination with rising drug prices and falling purity levels may suggest intensified law enforcement activity and thus a potential overall decline in drug supply.

It should be noted that reported seizures relate to events that took place in the past and in specific locations. In an environment where drug traffickers adapt quickly to changing risks and opportunities, drug trafficking patterns and flows derived from seizure data do not necessarily reflect the current modus operandi of traffickers in every detail. At the same time, experience has shown that some of the main drug-trafficking routes, once established, can prove rather resilient to change.

---


228 For the purposes of the present report, the analysis of NPS includes ketamine, which differs from other NPS in that it is widely used in human and veterinary medicine, while most NPS have little or no history of medical use.
remained relatively stable. A peak in heroin/illicit morphine seizures was reported in 2011, which initiated a period of much higher levels of seizures, driven by increased interceptions in Asia. Interceptions of ATS increased continuously from 2003 to 2013 in all regions, with the exception of Europe, where they remained stable. This may suggest the expansion of the ATS market to locations where some of these substances were not previously available.

Large variations in average size of drug seizures

With an average size of less than 1 kg per case over the past five years, seizures of heroin/illicit morphine and ATS are the smallest among all the drug types at the global level. The largest are seizure cases involving herbal cannabis (roughly 10 kg on average), while the average size of seizures of cocaine and cannabis resin is 5 kg and 3 kg, respectively. These differences may result from variations in trafficking modus operandi, whereby cocaine and cannabis products are smuggled in larger shipments than other drugs. Law enforcement may also target different levels of the supply chain depending on the drug. However, other elements such as drug price, market size, value and structure, the dynamics and structure of drug supply chains, as well as law enforcement priorities, would have to be explored before drawing clear conclusions on this subject.

The average size of seizure cases of all drugs, except ATS, has decreased in the past decade. This may reflect changes both in the targeting of law enforcement efforts and in trafficking patterns along the supply chain, but may also be the result of improved reporting of small seizure cases in some regions. The average size of seizures of a number of products decreased slightly between 2003 and 2013: heroin/illicit morphine decreased from 0.7 kg to 0.5 kg; cocaine decreased from 6.2 kg to 4.6 kg; and cannabis resin decreased from 4.3 kg to 3.9 kg. However, the average size of herbal cannabis seizures decreased substantially, from 23 kg to 7.8 kg, whereas the average size of ATS seizures doubled over the period, from 0.3 kg to 0.7 kg.

The Americas is the region where seizure cases are the largest on average. In the past five years, seizures of herbal cannabis in the region averaged 41 kg, while seizures of cocaine averaged 13 kg, seizures of ATS averaged 8 kg and seizures of heroin/illicit morphine averaged 3 kg: all significantly larger than in all other regions. It is worth noting, however, that the average size of seizure cases of all drugs in the Americas has decreased in the past decade, as has the number of seizure cases, with the exception of ATS, possibly suggesting an expansion of the ATS market in that region and comparatively greater targeting of ATS trafficking by law enforcement.

At the other end of the scale, the smallest seizures, in terms of their average size, are reported in Europe, irrespective of drug type. In the past five years, seizures of cannabis
Heroin is produced in three different regions, but while there is information from reports of individual seizures on the trafficking routes for heroin from Afghanistan, available data do not currently allow for the identification of the transit countries used in the trafficking of heroin from Colombia and Mexico or from the Lao People’s Democratic Republic and Myanmar. Pakistan is mentioned in individual drug seizure reports more frequently than other countries as a transit country for heroin seized elsewhere. This confirms that Afghan heroin is smuggled southwards from Afghanistan through Pakistan, but it may also suggest that this trafficking route is more successfully targeted by law enforcement in destination countries and/or that data reporting on the last departure country of the shipment seized is comparatively better for this route than for others.

Although opium poppy is cultivated in South-East Asia, individual drug seizures indicate that neither of the opium-cultivating countries in the region, the Lao People’s Democratic Republic and Myanmar, appears to be an important heroin trafficking departure hub. This may be due to the fact that Afghan heroin dominates the global market, but it may also reflect the fact that countries that report individual seizures are not markets for heroin produced in South-East Asia.

**Most seizures are made on road and rail, but the largest seizures are made at sea and in ports**

The frequency of use of different modes of transportation used by drug traffickers has not changed a great deal over the past decade. Accounting for nearly half the reported individual seizures in the 2009-2014 period, trafficking by road and rail is the most common mode of transportation used by traffickers globally, along with trafficking by air. The average size of drug shipments intercepted on road and rail increased substantially from 68 kg between 2006 and 2008 to 107 kg between 2009 and 2014.

Accounting for 8 per cent of all reported cases in the past six years, maritime trafficking remains the least common mode of transportation in terms of individual seizure cases, but maritime seizures tend to be comparatively very large. With an average weight of 365 kg per seizure in the 2009-2014 period (compared with 250 kg in the 2006-2008 period) maritime seizures are by far the largest among the three modes of transportation. This confirms that interception of maritime shipments has potentially the greatest impact on the total quantities of drugs smuggled, as well as on trafficking flows and the availability of illicit drugs at the global level. For example, parcel post was the most commonly detected method of drug importation at the Australian borders in 2013, yet just three maritime seizure

---

229 The present section is based on data from the individual drug seizure database. Reporting countries are asked to provide information on the country where the drugs were obtained (or, in the case of unaccompanied shipments, the departure country). For the purposes of this section, such locations are considered to be transit points of the drug.

230 The present section is based on data from the individual drug seizure database.
cases accounted for 74 per cent of the total weight of heroin intercepted that year in the country.

Traffic by air has become more frequent, but quantities intercepted remain comparatively small. Drugs being trafficked by air seized from 2009 to 2014 accounted for 46 per cent of global seizure cases, but at an average of 10 kg the size of the interceptions was much smaller. This represents an increase from the average of 6 kg per case observed in the period 2006-2008 and may reflect an increase in seizures involving trafficking by air cargo as opposed to air couriers.
Opium cultivation is reaching historic levels; prevalence of use remains stable

According to the limited information available, at 0.7 per cent and 0.4 per cent of the population aged 15-64 respectively, the global prevalence of use of opioids and opiates has remained stable, representing 32.4 and 16.5 million users. Due to a 7 per cent increase, from 209,000 ha in 2013 to 224,000 ha in 2014, opium cultivation in Afghanistan is now at its highest level since estimates became available, although the increase was actually greater from 2012 to 2013 (36 per cent) (see figure 39). The 63 per cent reduction in poppy eradication in Afghanistan, from 7,348 ha in 2013 to 2,692 ha in 2014, may be a contributing factor.

Following a consistent downward trend between 2000 and 2006, opium poppy cultivation in both the Lao People’s Democratic Republic and Myanmar increased steadily to reach roughly 64,000 ha in 2014, of which an estimated 57,600 ha were cultivated in Myanmar and 6,200 ha in the Lao People’s Democratic Republic.231

Only partial information about the extent of opium poppy cultivation and heroin production in the Americas is available, but Mexico eradicated 14,662 ha of opium poppy in 2013 (7 per cent less than in 2012) and Colombia estimated the area under opium poppy cultivation in 2013 to be 298 ha. Colombia also reported the eradication of 514 ha of opium poppy in 2013 and the dismantling of one heroin laboratory per year over the 2011-2013 period.

Global potential opium production also continued to increase in 2014, reaching 7,554 tons, its second-highest level since the late 1930s (see figure 40). Opium production in Afghanistan accounted for an estimated 85 per cent of that total (6,400 tons) and, at 410 tons of heroin of export purity, 77 per cent of global heroin production (estimated at 526 tons). The remaining 116 tons (heroin of unknown purity) were produced in the rest of the world, but because the conversion ratios were updated in 2014, potential heroin production in 2014 is not comparable with production in previous years.

The majority of the opium and illicit morphine seized in 2013 was concentrated around poppy cultivation areas in Afghanistan and its neighbouring countries, while heroin seizures covered a wider area (see figure 41). Since 2002, Afghanistan, Iran (Islamic Republic of) and Pakistan have consistently accounted for more than 90 per cent of the global quantity of opium seized each year and this pattern continued in 2013 when, with a 13 per cent increase from the previous year, the Islamic Republic of Iran remained the country with the largest quantity of opium seized (436 tons).

Globally, heroin seizures increased by 8 per cent from 2012 to 2013, whereas illicit morphine seizures decreased by 26 per cent (see figure 42). The largest drop in illicit morphine seizures was observed in Afghanistan, where they fell from 44 tons seized in 2012 to 24 tons in 2013. Since 2005, Afghanistan, Iran (Islamic Republic of) and Pakistan have accounted for more than 90 per cent of global morphine seizures each year, but in 2013 the quantity increased in the Islamic Republic of Iran (to 10.4 tons from 7 tons in 2012) and in Pakistan (to 3.8 tons from 1.4 tons in 2012).

Up-to-date information on the use of opiates was available in only a few countries and points to stable global demand for heroin, whereas the non-medical use of prescription

232 UNODC updated the conversion ratio from opium to heroin in 2014 and estimated export quality heroin to have a purity of 52 per cent. The updated conversion ratio is 9.6 kg of opium for the production of 1 kg of export quality heroin (52 per cent purity). For details, see Afghanistan Opium Survey 2014: Cultivation and Production, p. 35.

233 Islamic Republic of Iran, Drug Control Headquarters, Drug Control in 2013 (March 2014).
opiates has continued to increase in many regions. The markets for opiates in Africa, South-West Asia, parts of East Asia, the Middle East, Europe and Oceania are mainly supplied by South-West Asia (Afghanistan), while some markets in South-East Asia and Oceania are also supplied by South-East Asia (the Lao People’s Democratic Republic and Myanmar). The Americas are mainly supplied by Latin America (Colombia and Mexico), with the exception of Canada, which to a significant extent is supplied by Afghan heroin.

Shifts in opiate trafficking routes

Despite the increase in opium and illicit morphine seizures in the countries neighbouring Afghanistan, the stability of global seizures of heroin from 2008 to 2013 and of overall demand for heroin imply that the increase in estimated global opium and heroin production has not yet been reflected in a significant increase in heroin supply in most regions. There are signs, however, of increases in some heroin-related indicators (such as mortality and health emergencies) in the United States and the United Kingdom, where there are also indications of increased purity and lower prices. Moreover, in South and South-East Asia and West and East Africa, there are indications of increasing trafficking, but the paucity of data makes it difficult to determine whether these subregions are expanding markets for heroin.

The so-called “Balkan route” (through Iran (Islamic Republic of) and Turkey overland via South-Eastern Europe to Western and Central Europe), the so-called “northern route” (through Central Asia to the Russian Federation) and the so-called “southern route” (southwards through Iran (Islamic Republic of) or Pakistan) are the established global trafficking routes of Afghan opiates. These routes are marked, however, by constant changes; for example, two major heroin seizures in Armenia (917 kg) and Georgia (588 kg) reported in 2014 were in stark contrast to the very low levels of seizures made in those countries over the past 15 years. This suggests that drug trafficking networks may be experimenting with new

---

There is no evidence of a decline in the demand for heroin in the Russian Federation, yet heroin seizures along the northern route have actually decreased. Despite a temporary reduction from 2011 to 2013, the fact that heroin seizures in Afghanistan itself have increased in the past decade may show that an increasing amount of opiates are being intercepted before reaching markets outside Afghanistan. On the other hand, several countries reported increasing seizures of heroin trafficked via the southern route (on which heroin is trafficked to Asia and Europe often via African countries) as well as maritime routes, which is consistent with reports of an expansion of trafficking along the southern route. In Pakistan, opium seizures increased for the third consecutive year to reach 34 tons in 2013. The strengthening of controls between Afghanistan and Iran (Islamic Republic of) and between Iran (Islamic Republic of) and Turkey may have forced traffickers to move southwards towards the coasts of Iran (Islamic Republic of) and Pakistan.

The increasing importance of Africa as a transit region for Afghan heroin bound for Europe and other regions has been reflected in increasing seizures of heroin being reported in recent years by some African countries, particularly in East Africa, and in seizures in Europe of African provenance. Since 2010, heroin seizures associated with the southern route have been reported in a number of European countries, including Austria, Belgium, the Czech Republic, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Lithuania, the Netherlands, Portugal, Serbia, Slovenia, Spain, Sweden, Switzerland, Ukraine and the United Kingdom (see table 6 and figure 43). It is not clear whether this is a long-term shift away from the Balkan route or simply a response to opportunities...
presented by perceived lower levels of law enforcement along the southern route.\textsuperscript{238}

Although suspected for decades,\textsuperscript{239} recent seizure data suggest that movements of large shipments of heroin from Afghanistan across the Indian Ocean to East and Southern Africa may have become more common. Dhows (traditional sailing vessels used in the Red Sea and the Indian Ocean) are known to move opiates from Afghanistan to Kenya and the United Republic of Tanzania.\textsuperscript{240} In 2014, more than 2,200 kg of heroin were seized on the Indian Ocean by the Combined Maritime Forces,\textsuperscript{241} which is more than the total reported heroin seizures for the whole of Africa between 2011 and 2013. In Kenya, 377 kg of heroin and 33,200 litres of liquid heroin were seized in 2014 from a single ship transiting via the Islamic Republic of Iran that was destined for Mombasa, Kenya; in the United Republic of Tanzania, a single record seizure of 1,032 kg of heroin transiting via Pakistan and smuggled to the country by dhow was reported;\textsuperscript{242} while in West Africa, Nigeria reported the seizure of 25 kg of heroin bound for North America and Western and Central Europe in 2013. Thus, there are increasing signs of parallels with the phenomenon in the 2000s, when Africa began to play a strategic role in the trafficking of cocaine.

\textsuperscript{238} UNODC, Afghan Opiate Trafficking through the Southern Route, 2015 (Vienna, 2015).

\textsuperscript{239} United States, Drug Enforcement Administration (DEA), Drug Trafficking from Southwest Asia: Drug Intelligence Report (August 1994).


\textsuperscript{241} Combined Maritime Forces is a multinational naval partnership that operates in international waters, encompassing some of the world’s most important shipping lanes in the Indian Ocean and adjoining bodies of water.

\textsuperscript{242} UNODC, Afghan Opiate Trafficking through the Southern Route, 2015 (Vienna, 2015).

\textsuperscript{243} UNODC, World Drug Report 2014.
heroin and a decrease in its price in some parts of the country. A recent household survey in the United States indicated that there was a significant decline in the misuse of prescription opioids from 2012 to 2013.244

The number of drug-related deaths continues to rise in the United States, with heroin-related cases increasing considerably (from 5,925 deaths in 2012 to 8,257 in 2013) to reach their highest levels in the past decade.245 Prescription painkiller overdoses also continue to rise, particularly among women. Over the period 2004-2011, emergency room cases related to heroin and other opioid use rose by 183 per cent (see figure 45).246

Seizures of heroin in the United States have increased since 2008 (to 6.2 tons in 2013). Authorities have reported increased trafficking of both Mexican- and South American-produced heroin247 and, in 2014, Mexico reported being a transit country for heroin produced in Colombia and destined for the United States.248 Indeed, the majority of heroin in the United States is estimated to be supplied by Latin American production.249 In 2011 and 2012, however, authorities suggested that the availability of Afghan heroin was increasing in the United States,250 although current estimates of its share of consumer markets have not been made available to UNODC (past estimates pointed to a market share of around 4 per cent).251 Seizures of Afghan opiates made on the southern route in Africa destined for the United States seem to confirm that organized criminal groups may be trafficking heroin to supply the growing market in the United States.252

Unlike all the other countries in the Americas, Canada is not supplied to a large extent by Latin American heroin. According to the Royal Canadian Mounted Police National Intelligence Coordination Center, between 2009 and 2012, at least 90 per cent of the heroin seized in Canada originated in Afghanistan.253 The southern route was reportedly the major conduit for those shipments, with nearly 50 per cent having transited through India, Iran (Islamic Republic of) and Pakistan.254,255

Australia: a mixed market with constant changes in supply source

Levels of opioid use in Australia and New Zealand remain high (2.9 per cent), mainly because of high levels of misuse of prescription opioids. According to a recent survey in Australia, there has been an increase in the misuse of prescription opioids (from 3.0 per cent in 2010 to 3.3 per cent in 2013), while the prevalence of heroin use has declined from 0.2 to 0.1 per cent.256

There are also signs of changes in the heroin market in Oceania. The number of heroin seizures made at the Australian border increased in 2013 from the previous year, with 429 kg being intercepted, confirming the increasing trend since 2004. Most of the heroin seized in Australia in 2013 originated in South-East Asia, while in previous

244 United States, SAMHSA, Center for Behavioral Health Statistics and Quality, Results from the 2013 National Survey on Drug Use and Health: Detailed Tables, NSDUH Series H-46, HHS Publication No. SMA 13-4795 (Rockville, Maryland, 2014), tables 7.20B and 7.30B.
247 United States, DEA, National Drug Threat Assessment Summary (November 2013).
249 “In 2012, heroin from South America accounted for 51 per cent (by weight) of the heroin analysed through the DEA Heroin Signature Program, while heroin from Mexico accounted for 45 per cent and heroin from South-West Asia accounted for 4 per cent”; see United States, DEA, National Drug Threat Assessment Summary, 2014 (November 2014), p. 9.
250 UNODC, responses to the annual report questionnaire submitted by the United States for 2011 and 2012.
252 UNODC, Afghan Opiate Trafficking through the Southern Route, 2013 (Vienna, 2015).
253 UNODC Vienna southern route study conference: view from Canada, presentation by the Royal Canadian Mounted Police.
254 UNODC regional workshop on Afghan opiate trafficking on the southern route (Vienna, March 2014).
years the supply fluctuated between heroin originating in South-East Asia and South-West Asia (see figure 47). In 2013, by number of seizures, the Netherlands, Viet Nam and Thailand (in descending order) were the primary embarkation points of heroin reaching Australia, while Thailand, Viet Nam, Taiwan Province of China and Malaysia (also in descending order) were the principal last departure points in terms of quantities seized.257

Europe: a diverging heroin market with emerging supply routes

The heroin market in Europe is marked by variations across subregions. In Western and Central Europe, there are indications of a stable or downward trend in the use of heroin, but in Eastern and South-Eastern Europe, the prevalence of use of heroin remains high.

Quantities of heroin seized in Europe accounted for almost 30 per cent of all heroin seized globally in 2013. Heroin seizures in South-Eastern Europe increased slightly in 2013 from the previous year, with Turkey seizing 13.5 tons, slightly more than the 13.3 tons reported in 2012. A recent government report in Turkey258 highlighted several new developments, including an increase in heroin arriving in Turkey from Iraq rather than exclusively from the Islamic Republic of Iran, the increasing use of sea containers in heroin trafficking and the diversification of the activities of organized criminal groups, which are trafficking not only heroin but also cannabis resin and methamphetamine.

The quantities of heroin seized in Eastern Europe increased slightly in 2013, but remained stable from a long-term perspective. Opioid use in Eastern Europe, in particular in the Russian Federation and Ukraine, remains high, with an estimated 2.37 million (2.29 per cent prevalence), including 291,500 opiate users (0.9 per cent prevalence). Opioid use in the other countries in the subregion remains lower than the global average, although experts in Belarus perceive an increase in opioid use, particularly of acetylated opium and pharmaceutical opioids. Also, in the Russian Federation the replacement of heroin with cheaper alternatives such as acetylated opium and desomorphine continues to be reported.259 A major health consequence of people injecting opioids in Eastern Europe is the high prevalence of HIV, which is estimated to be 24.6 per cent in the Russian Federation and 19.7 per cent in Ukraine, and accounts for a third of the global estimated number of PWID living with HIV in the region. In the Russian Federation, drug-related deaths due mainly to opioid overdose are also reported to be high, at 80 deaths per million of the population.

In Western and Central Europe, seizures of heroin in most countries either remained stable or continued to decline gradually, except in Belgium, where seizures of heroin increased dramatically, from 112 kg in 2012 to 1.2 tons in 2013, as a result of two large seizures. It is important to mention that some large maritime seizures were made in Western and Central Europe, which suggests that significant heroin shipments were not detected at points of departure and transit, whether in South-West Asia, the


258 Turkish National Police, Department of Anti-Smuggling and Organized Crime, Turkish Drug Report 2013 (Ankara, 2014).

259 UNODC, responses to annual report questionnaire by Russian Federation 2012-2013.
Middle East or Gulf countries. This also suggests that the ports of Belgium and the Netherlands may play a key role as entry points to Europe for heroin imported from Afghanistan via the southern route.\(^{260}\)

Other opioids, such as buprenorphine, fentanyl and methadone, are available in illicit markets in Western and Central Europe. For example, fentanyl and buprenorphine are the main opioids used in Estonia and Finland, respectively. In some instances, these substances account for a significant proportion of overdose deaths, as in the case of fentanyl in Estonia. On the other hand, injecting heroin has been declining in Western and Central Europe,\(^{261}\) as has the number of heroin users entering treatment for the first time, resulting in an ageing cohort of heroin users currently in treatment.

In the United Kingdom, following a decrease in 2011, there was an increase in heroin-related deaths in 2013. This increase may be partially explained by an increase in heroin purity which, having been low in 2011 and 2012, rose to almost its 2010 level in 2013. The average wholesale price of heroin in the United Kingdom decreased slightly from £30,000 per kilogram in 2012 to £28,000 in 2013,\(^{262}\) which may indicate an increase in the heroin supply and may also be related to the increase in production in Afghanistan.

Heroin is trafficked to Europe via the Balkan route and the northern route, but heroin shipments from Iran (Islamic Republic of) and Pakistan are also entering Europe by air or sea, either directly or transiting through countries in East and West Africa. The quantity of heroin seized in Europe over the past decade has varied greatly and, since 2010, supplies of heroin to the United Kingdom from Afghanistan via the Balkan route have decreased. Belgium and the Netherlands remain important transit points for heroin trafficking to the United Kingdom via heavy goods vehicles and ferries.\(^{263}\)

**Increase in heroin seizures in East and South-East Asia**

In the absence of any recent reliable data on the extent of the use of opioids in most parts of Asia it is difficult to determine a trend, although, based on expert perceptions, it is considered to be generally stable. Expert perceptions of trends in drug use indicate that opioid (including heroin) use is perceived to be decreasing in China, where, although the total number of registered heroin users increased by 6 per cent in 2013, to 1.32 million heroin users increased by 6 per cent in 2013, to 1.32 million heroin users, the proportion of heroin users among all registered drug users decreased. This was because of an increase in the proportion of users of synthetic opioids, which may also include opiate polydrug users (see figure 50).

Historically, the southern route has been a marginal conduit for Afghan opiates trafficked to East and South-East Asia, as opiates produced in Myanmar tend to feed that market. There have been various reports, however, that Myanmar may be unable to meet regional demand, and

---

263 UNODC, responses to annual report questionnaire by the United Kingdom.
that heroin is trafficked to East and South-East Asia from Afghanistan.\textsuperscript{264} It is quite likely that a portion also travels north from Afghanistan overland via Central Asia to China,\textsuperscript{265} the primary consumer in the Asia region.\textsuperscript{266}

Amounting to 11.8 tons in 2013, seizures of heroin in East and South-East Asia increased for the third consecutive year. China continued to account for the majority of heroin seizures in the region, with annual seizures of 8.5 tons, up from 7.3 tons in 2012. The authorities in China reported that northern Myanmar remained the main source of heroin in the Chinese market, but also noted some cases of seizures of opiates originating in Afghanistan.\textsuperscript{267}

\textbf{Africa: possible increase in heroin use}

Although information on the extent of drug use in Africa is limited, according to UNODC the prevalence of use of opiates is estimated at 0.3 per cent of the population aged 15-64 (an estimated 1.88 million users). Moreover, the increasing importance of Africa as a transit area for Afghan heroin bound for markets in other regions may have led to an increase in heroin use locally.

\begin{figure}
\centering
\includegraphics[width=\textwidth]{fig50.png}
\caption{Trends in registered drug users and the proportion of registered drug users, by drug type in China, 2002-2013}
\end{figure}

\textbf{Source: UNODC, responses to annual report questionnaire and other official sources.}

\begin{figure}
\centering
\includegraphics[width=\textwidth]{fig51.png}
\caption{Number and weight of annual Afghan heroin seizures in China, 2009-2013}
\end{figure}

\textbf{Source: “Afghan opiate trafficking on the southern route: statistics, seizures and recent trafficking trends in China”, presentation by the National Narcotics Control Commission of China, UNODC regional workshop on Afghan opiate trafficking on the southern route, Vienna, March 2014.}

\textsuperscript{264} UNODC, \textit{Afghan Opiate Trafficking through the Southern Route}, 2015 (Vienna 2015).


\textsuperscript{266} Even more confusingly, at times traffickers seem to use western China as a transit zone between Pakistan and Central Asia (based on seizure data reported by the World Customs Organization).

Lowest levels of coca bush cultivation on record

Coca bush cultivation continued to decline in 2013, reaching its lowest level since estimates from the mid-1980s. The decline in 2013 was driven mainly by an 18 per cent decrease in coca bush cultivation in Peru (from 60,400 ha in 2012 to 49,800 ha) and by a 9 per cent decrease in the Plurinational State of Bolivia (from 25,300 ha to 23,000 ha).

Coca bush cultivation in Colombia, on the other hand, remained stable in 2013, although it remained at historically low levels. In addition to the figure collected on 31 December 2012, available information for Colombia on the presence of coca bush cultivation shows that prior to eradication 89,215 ha were under cultivation at some point in 2013, 34 per cent less than in 2012. The potential production of pure cocaine in Colombia was estimated at 290 tons, the lowest level since 1996. The combination of a decrease in cultivation in all the main coca bush cultivating countries has led to a decline in the estimated global production of cocaine. It should be noted that the illicit extraction of cocaine alkaloids from coca leaves, the first step in the manufacture of cocaine, continues to take place almost exclusively in the three coca-producing countries, which also accounted for the majority of cocaine hydrochloride manufactured worldwide.

Cocaine markets: the impact of decreasing production

The global supply of cocaine may originate in Bolivia (Plurinational State of), Colombia and Peru, but the largest cocaine markets and highest rates of prevalence of cocaine use are reported in North and South America and Western and Central Europe. Estimated at 0.4 per cent of

268 UNODC and Colombia, Colombia: Coca Cultivation Survey 2013 (Bogotá, June 2014).

269 The methodology used to estimate potential cocaine production was adjusted and thus not comparable with the last report. For more information on the adjustment, see Colombia: Coca Cultivation Survey 2013 cited above.
the global adult population aged 15-64, the annual prevalence of cocaine use has shown a declining trend in Western and Central Europe and North America, particularly the United States, over the past few years, but cocaine use still remains at high levels in those subregions, while information for most of Africa and Asia remains sporadic.

Cocaine is usually trafficked northwards from the Andean countries of South America to North America and across the Atlantic to Europe via the Caribbean or Africa, by a variety of means, including air and sea. Individual drug seizure cases reported to UNODC show that maritime trafficking has increased as a means of transporting large quantities of cocaine in recent years, accounting for 60 per cent of the total quantities seized (see figure 53). Accounting for more than 50 per cent of actual seizure cases, trafficking by air is very frequent but the quantities intercepted are comparatively small (average of 6 kg per case in the period 2009-2014) (see figure 54).

The fact that coca bush cultivation continued to decrease in 2013, reaching its lowest level in the past three decades, may partially explain the shrinking of some cocaine markets and the reduction in the availability of cocaine in, for example, the United States and, more recently, in Canada. Successful law enforcement efforts and conflicts between transnational criminal groups have also had an impact on the availability of cocaine.

Following the increase observed between 2011 and 2012, cocaine seizures have remained stable (687 tons seized in 2013 compared with 684 tons in 2012), despite a decrease in seizures in the two main cocaine markets, the United States (65 per cent decrease, from 104 to 37 tons) and...
CONTINUED INCREASE IN COCA ERADICATION AND THE DISMANTLING OF LABORATORIES

The manual eradication of coca bush in the Plurinational State of Bolivia continued to increase in 2013, reaching 11,407 ha, while seizures of coca leaf dropped significantly compared with 2012. The authorities in Peru eradicated over 23,900 ha of coca bush crops in 2013, with most of it focused on the Palcazú-Pichis-Pachitea area and the Monzón Valley, which had the highest rates of expansion in the area used for cultivation and which serve as key points for the production of illicit coca derivatives produced both locally and elsewhere. Because of eradication efforts and the subsequent decrease in the supply of coca leaf, the average price of dried coca leaf in Peru increased by 30 per cent in 2013. Authorities reported that state eradication efforts in recent years have caused drug trafficking organizations to shift illicit cultivation to increasingly scattered and isolated areas. In Colombia, supply reduction activities in 2013 included the aerial spraying of over 47,000 ha of coca bush and the manual eradication of over 22,000 ha.

Clandestine cocaine-processing laboratories also exist outside the main cocaine-producing countries. In 2013, a number of countries in South America, including Argentina, Chile, Ecuador and Venezuela (Bolivarian Republic of), reported the detection of clandestine laboratories processing coca leaf derivatives, but the overall number of laboratories dismantled has decreased since 2011. Two European countries also reported the detection of clandestine laboratories processing coca leaf derivatives; however, cocaine laboratories detected outside South America are usually secondary extraction laboratories for extracting cocaine from other materials, such as clothing or plastics, used for trafficking and concealment purposes. In the Plurinational State of Bolivia, the number of cocaine hydrochloride laboratories destroyed by authorities increased by 81 per cent to 67 in 2013. During 2013, the authorities in Colombia destroyed a total of 2,128 laboratories for the extraction of coca paste or cocaine base, as well as 208 cocaine hydrochloride laboratories.

Cocaine-type laboratories dismantled, 2011-2013

![Graph showing the number of cocaine-type laboratories dismantled, 2011-2013.](image)

Source: UNODC, responses to annual report questionnaire and other official sources.

---

Source: UNODC, individual drug seizure database.

Note: Excludes cases in which the mode of transportation was unknown, not applicable or specified as “other”. The values in the figure are based on 4,714 seizure cases by air, 5,817 cases by road and rail and 244 maritime cases, for 2006-2008. For 2009-2014, the figures are based on 13,058 seizure cases by air, 8,415 cases by road and rail and 843 maritime cases.
Western and Central Europe (18 per cent decrease, from 71 to 58 tons) (see figure 55). The only region where cocaine seizures increased in 2013 was Central America and the Caribbean, up to 162 tons in 2013 from 78 tons in 2012.

In 2013, Colombia again reported the largest annual cocaine seizures by a single country worldwide, even though its seizures of cocaine base, paste and salts decreased from 243 tons in 2012 to 226 tons in 2013. Authorities in Colombia reported frequently meeting resistance when conducting supply reduction activities, such as monitoring coca bush cultivation and cocaine production, which may have had an impact on seizures.

North America: shrinking cocaine market

Supply reduction measures may have led to a reduction in the size of the cocaine market in some areas of the world, reflected in the decrease in the number of seizures made and in the decline in the prevalence of cocaine use. Compared with previous years, there was a decrease in the amount of cocaine seized while entering Canada in 2013. Most cocaine seizures came from the Caribbean, Central and South America and, to a lesser extent, the United States, via air cargo, mail and passenger luggage, with most cocaine entering Canada via the major sea ports. Some of the possible explanations for the shrinking of the cocaine market in Canada are changes in consumer preferences and a shift in tactics and routes by criminal organizations in an attempt to avoid law enforcement detection.

In 2013, the prevalence of cocaine use in the United States was estimated to be 1.6 per cent of the population aged 12 and older, and this has remained stable over the past few years, although it is still significantly lower than in 2006. Cocaine use among high-school students has been declining, with annual prevalence nearly halving since 2006, when it was reported to be 3.5 per cent, to 1.8 per cent in 2013. The proportion of young people who perceive that cocaine is easy to obtain has also declined in recent years.

South America: increase in cocaine use

Long-term trends show that the quantity of cocaine seized globally has remained stable, with South American countries continuing to account for the majority of cocaine seizures made worldwide. In South America, the annual prevalence of cocaine use was estimated to have increased from 0.7 per cent in 2010 (1.84 million users) to 1.2 per cent in 2012 (3.34 million users), three times the global estimated average level of consumption and it remained at the same level in 2013. Experts in Chile and Costa Rica perceived an increase in cocaine use in previous year data, but the increase in cocaine use in the subregion is driven by increasing use in Brazil, which is the largest cocaine market in South America. While no recent survey has been undertaken in Brazil, extrapolating data from a survey among university students, UNODC estimates a prev-
ience of use of cocaine of 1.75 per cent among the adult population of the country. Because of its geographical position, Brazil plays a strategic role in the trafficking of cocaine, seizures of which doubled in the country in 2013 to over 40 tons. Cocaine enters Brazil by air (small aircraft), land (car, truck and bus) and river (boat across the Amazon and its tributaries), before being shipped overseas, mainly to Europe, either directly or via Africa (roughly 30 per cent of the cocaine seized in the country is intended for external markets), using containers and aircraft.

Seizures of cocaine (base, paste and salts) decreased in Bolivia (Plurinational State of), Peru and Venezuela (Bolivarian Republic of) in 2013. In the Plurinational State of Bolivia, cocaine seizures reached their lowest level since 2007. In Peru, seizures of cocaine paste peaked in 2012, but decreased to 10.8 tons in 2013, while seizures of cocaine salt rose slightly to 13.3 tons in 2013. In the Bolivarian Republic of Venezuela, cocaine seizures decreased to 20.5 tons in 2013 (from 27.6 tons in 2012). According to authorities in the Bolivarian Republic of Venezuela, the country remains a transit point for cocaine, particularly cocaine trafficked by air in private aircraft, but newly introduced legislative changes related to air traffic control have decreased the entry and exit of uncontrolled aircraft, which has led to a decrease in drug trafficking by air.

Three European countries listed the Bolivarian Republic of Venezuela as a significant departure or transit country for cocaine in 2013.

**Australia: more people are using cocaine but with less frequency**

In Australia, while the use of drugs such as cannabis, “ecstasy”, methamphetamine and amphetamine has generally declined since 2004, the number of people using cocaine has been increasing since that time (see figure 57). The frequency of use of cocaine by recent users has decreased, however, with a lower proportion using it in the past month (18 per cent) and a higher proportion using it only once or twice a year (71 per cent). There was an increase in the proportion of people who were offered or had the opportunity to use cocaine in 2013 (up to 5.2 per cent from 4.4 per cent in 2010), despite increases in the retail price in recent years. Users’ perceptions about the harmfulness of the substance have decreased to 3.6 per cent of people considering cocaine the drug of most serious concern, which may partly explain the increase in the number of people having tried cocaine.

In New Zealand, the cocaine market remains very limited, with a little over 228 g of cocaine seized in 2013, and its use seems to rarely come to the attention of health agencies.

---

271 Country report submitted by Brazil to the Twenty-fourth Meeting of Heads of National Drug Law Enforcement Agencies, Latin America and the Caribbean.

272 UNODC, annual report questionnaire, replies submitted by Venezuela for 2013 and country report submitted by Venezuela to the Twenty-fourth Meeting of Heads of National Drug Law Enforcement Agencies, Latin America and the Caribbean.

273 France, Poland and Spain.

Europe: stable cocaine market

Cocaine use remains high in the main markets of Western and Central Europe (around 1.0 per cent of the population aged 15-64). There are some signals, however, of a decreasing trend in countries with high levels of use, such as Denmark, Italy and Spain, whereas the United Kingdom reports a rising trend in cocaine use in the past year (see figure 59) and most of the remaining countries report stable or declining trends in cocaine use. There is also a declining trend in treatment demand for cocaine use, which may indicate a decline in the European cocaine market.

Based on seizure data, cocaine continues to be the third most trafficked drug in Europe, after herbal cannabis and cannabis resin. In recent decades, with the development of new routes, cocaine trafficking (and use) in Europe has evolved and become more complex. The quantities of cocaine intercepted in Europe increased from the mid-1990s, reaching a peak in 2006 (121 tons) before declining to an average of 62 tons between 2008 and 2013. Seizures in the Iberian Peninsula, which is used as a major entry point for cocaine to Europe, reached a peak in 2006, before falling until 2012. However, quantities seized in 2003 increased, possibly reflecting a change in law enforcement priorities or a change in the modus operandi of traffickers. As cocaine is often perceived to be an elite drug, the economic climate may account for the decrease in seizures and a possible related decrease in cocaine use.

Eastern Europe has seen an increased number of cocaine interdictions in recent years, although of small quantities, which may suggest that the cocaine market is moving east-wards.275 Expert perceptions of trends in the use of cocaine in the Russian Federation point to an increase, while it is perceived to be stable in the other countries in the subregion.

Central America and the Caribbean: transit points for cocaine trafficking

The prevalence of use of cocaine remained high in Central America and the Caribbean in 2013, and the subregion continued to be reported as a transit area for cocaine trafficked to Europe. Trafficking patterns in Central America appeared to be relatively stable, with Panama (41 tons) and Costa Rica (20 tons) seizing the largest quantities of cocaine in the region in 2013. Costa Rica reported that it had changed from being primarily a transit country to a country of both transit and temporary storage. Trinidad and Tobago seized 2.3 tons of cocaine in 2013, surpassing the previous annual record of 1.9 tons in 2005. Law enforcement authorities have observed a change in trafficking patterns in which drug traffickers and smugglers cancel confirmed flights at the last minute then make hasty bookings in an attempt to avoid detection during passenger screenings.

Africa: still a transit hub for cocaine trafficked to Europe

Information about the extent of cocaine use and trafficking in Africa is limited, but prevalence estimates of cocaine use for Southern Africa and West and Central Africa indicate a high prevalence of use (0.7 per cent annual prevalence in 2013). The use of the African continent as a trans-shipment region for cocaine trafficking to Europe continues, with countries in West Africa being reported as transit countries. Nigeria reported the seizure of 290 kg

---

Illicit coca bush cultivation and coca leaf transformation into cocaine lead to serious environmental damage. Coca bush cultivation takes place in the northern-Andean ecosystem, a biodiversity hotspot\(^a\) and the most species-rich region on Earth\(^b\), where coca bush cultivation has devastating effects. Deforestation is the most researched aspect of the impact on the environment.\(^c\) Recent studies using satellite images\(^d\) have given a clearer picture of the damage caused to vegetation. In Colombia alone, roughly 290,000 ha of forest were lost directly to coca bush crops between 2001 and 2013.\(^e\) The slash-and-burn technique is used to clear new plots using fire,\(^f\) which destroys the vegetative matter that would otherwise protect the soil. Besides forest loss, this also leads to increased erosion. As farmers move to undeveloped areas, additional land is cleared to establish subsistence crops. Thus, even though coca bush cultivation has decreased, the percentage of deforestation caused by the cultivation has increased. Recent studies have found that proximity to coca bush crops increases the probability of forest loss, and that deforestation is “contagious” in areas where coca bush is grown.\(^g\) Moreover, the presence of coca bush cultivation in natural parks\(^h\) increases the negative impact on biodiversity.

![Graph showing deforestation due to coca bush cultivation in Colombia, 2001-2013](image)

**Sources:**
- UNODC, *Colombia: Coca Cultivation Survey 2014; Coca Cultivation in the Andean Region: a Survey of Bolivia, Colombia and Peru* and Bradley and Millington, "Coca and colonists: quantifying and explaining forest clearance under coca and anti-narcotics policy regimes".
- Ibid.
- UNODC, *Coca Cultivation in the Andean Region: a Survey of Bolivia, Colombia and Peru* (June 2006), part 2.

---

Asia: stable but limited cocaine use

Mostly limited to countries in East and South-East Asia and the Near and Middle East, cocaine use in Asia remains comparatively low at a prevalence of 0.05 per cent among the population aged 15-64 (an estimated 1.3 million users). Quantities of cocaine seized have remained stable over the past three years, with some 2 tons intercepted in the region in 2013. However, exceptionally large amounts of cocaine are reported each year in some Asian countries; for example, roughly 1 ton was seized in Pakistan in 2013. Larger than amounts seized in the past, this suggests that cocaine is trafficked in the region and that pockets of use may be emerging in parts of Asia.

---

\(^{276}\) Country report submitted by the United Republic of Tanzania to the Twenty-fourth Meeting of Heads of National Drug Law Enforcement Agencies, Africa.
Cannabis cultivation: a global phenomenon

Cannabis plants are grown almost everywhere in the world, making global levels of cannabis cultivation and production difficult to estimate. Herbal cannabis is produced in almost every country, while the production of cannabis resin is confined to a few countries in North Africa, the Middle East and South-West Asia. Morocco reported 47,196 ha of cannabis cultivation in 2013, a slight decrease compared with the 52,000 ha reported in 2012, while Mongolia reported 15,000 ha of land covered by cannabis. With 10,000 ha under commercial cannabis plant cultivation in 2012, producing some 1,400 tons of cannabis resin, one of the largest producers of cannabis resin is Afghanistan, where cannabis cultivation is linked to opium poppy cultivation: 38 per cent of villages where opium poppy is grown also report cannabis plant cultivation, compared with only 5 per cent of non-poppy-growing villages.277

Increasing cannabis seizures, with regional differences

Cannabis plant cultivation sites range from small-scale, home-growing sites to large-scale industrial farms. Cannabis plant cultivation techniques and equipment have seen an increase in professionalism and innovation, resulting in an increase in the capacity of cannabis plant growers to avoid detection by law enforcement; yet 2013 data show an increase in quantities seized of both herbal cannabis and cannabis resin worldwide (see figure 61 and figure 62). This bucks the declining trend in seizures of herbal cannabis that began in 2011 and may point to increased law-enforcement activities and/or an increase in cannabis production and trafficking, albeit with geographical variations.

Individual drug seizure cases reported to UNODC show that trafficking by land accounted for more than 60 per cent of the total quantities seized and number of cases, with an average of 190 kg per seizure case in the period 2009-2014. Maritime trafficking is the second most

---

TABLE 8. Reported eradication of cannabis plants, 2013

<table>
<thead>
<tr>
<th></th>
<th>Eradication (outdoor)</th>
<th>Eradication (indoor)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Plants (no.)</td>
<td>Sites (no.)</td>
</tr>
<tr>
<td>United States</td>
<td>4,024,605</td>
<td>6,376</td>
</tr>
<tr>
<td>Philippines</td>
<td>2,013,678</td>
<td>451</td>
</tr>
<tr>
<td>Guatemala</td>
<td>2,000,000</td>
<td>n.a.</td>
</tr>
<tr>
<td>Costa Rica</td>
<td>1,461,747</td>
<td>199</td>
</tr>
<tr>
<td>Brazil</td>
<td>900,744</td>
<td>n.a.</td>
</tr>
<tr>
<td>Italy</td>
<td>884,612</td>
<td>1,100</td>
</tr>
<tr>
<td>Trinidad and Tobago</td>
<td>597,100</td>
<td>117</td>
</tr>
<tr>
<td>Ukraine</td>
<td>483,000</td>
<td>n.a.</td>
</tr>
<tr>
<td>Belgium</td>
<td>393,888</td>
<td>1,107</td>
</tr>
<tr>
<td>New Zealand</td>
<td>105,321</td>
<td>n.a.</td>
</tr>
</tbody>
</table>

Source: UNODC, responses to annual report questionnaire and other official sources.
Note: n.a. = not available.

FIG. 61. Global quantities of cannabis resin seized, by region and in selected countries, 2003-2013

FIG. 62. Global quantities of herbal cannabis seized, by region and in selected countries, 2003-2013

Source: UNODC, responses to annual report questionnaire and other official sources.
common method of transportation, but the quantities intercepted are comparatively larger, with an average of 387 kg per seizure case in the same period (see figure 63).

The trend in Europe and Latin America and the Caribbean never actually underwent a decline. The contribution of Latin America and the Caribbean to total global quantities of herbal cannabis seized increased from 20 per cent to 30 per cent in 2013, but the largest quantities of herbal cannabis were seized in North America (47 per cent). The global increase in quantities of cannabis resin seized in 2013 was mainly driven by the rise in Pakistan, from 166 tons in 2012 to 314 tons in 2013, which counteracted the marked decrease in the quantities of cannabis resin reported as seized in Afghanistan. Quantities intercepted in North Africa increased by 31 per cent, mainly owing to increases in Algeria (from 157 tons in 2012 to 212 tons in 2013) and Egypt (from 12 tons to 84 tons), and despite a decrease in Morocco from 137 tons in 2012 to 107 tons in 2013. Spain accounted for 23 per cent of global quantities of cannabis resin seized in 2013.

The Americas: increase in cannabis use and related problems in the United States

With an annual prevalence of use of 8.4 per cent among the population aged 15-64, cannabis is the most widely used illicit substance in the Americas, driven mainly by the high level of use in North America (11.6 per cent). The most recent data point to an increase in the prevalence of cannabis use in the United States, which, because of ongoing changes in legislation in some states, has drawn special attention.

Cannabis use among high-school students in the United States increased in 2013 (from 24.7 per cent in 2012 to 25.8 per cent annual prevalence in 2013), but there has been a significant decline in the use of synthetic cannabis to an annual prevalence of 6.4 per cent in 2013 from 8 per cent in 2012, when it was first included in a school survey. Available data show an increasing trend in cannabis-related treatments in the past decade, along with increasing cannabis-related hospital admissions.

Although the largest quantities of herbal cannabis were still seized in North America (47 per cent), the United States reported decreases in seizures between 2009 and 2013 (see figure 65). Seizures in Mexico followed a similar trend, decreasing between 2010 and 2013. Despite these recent decreases, the United States and Mexico still account for the majority of global herbal cannabis seizures.

Mexican authorities report the production of herbal cannabis for both local consumption and for trafficking to the United States, mainly over land, in private vehicles and buses, using various methods of concealment.

Recent data show an increase in cannabis use in South America, especially in Chile (7.5 per cent annual prevalence of use) and Colombia (3.3 per cent), while herbal

cannabis seizures increased sharply from 821 tons in 2012 to 1,308 tons in 2013, owing to significant seizures in Paraguay (462 tons), Colombia (408 tons) and Brazil (222 tons). It is noteworthy that, in the context of international police cooperation in this region, Brazil and Paraguay conduct joint operations to eradicate marijuana in Paraguay. The Brazilian Federal Police also perform eradication operations in the northeast of Brazil.283

Europe: increase in cannabis market indicators, but prevalence of use remains stable

Europe is one of the world's largest consumer markets for cannabis resin, yet the market in Western Europe may now be dominated by herbal cannabis. Of the estimated 2,050 tons of cannabis consumed in the European Union and Norway in 2012, 1,280 tons were estimated by EMCDDA to be herbal cannabis, the use of which is more evenly spread across European countries than the use of cannabis resin, which is concentrated in a few countries.284

The quantity of herbal cannabis seized in Europe increased from 284 tons in 2012 to around 362 tons in 2013, primarily due to seizures in South-Eastern Europe. Seizures of cannabis resin also increased in Europe from 480 tons in 2012 to 560 tons in 2013, again primarily due to seizures in South-Eastern Europe, specifically in Turkey, where seizures of cannabis resin increased from 27 tons in 2012 to 94 tons in 2013. However, quantities of cannabis resin seized in Spain, where cannabis resin seizures are the largest in Europe, have decreased for five consecutive years; almost all of the cannabis resin that enters the country continues to be of Moroccan origin and the main mode of transportation is by sea, in speedboats, sailboats and fishing vessels.

In recent years, the price and potency of cannabis products in Europe has increased.285 In countries with available information, there has been an increase in both the cultivation of cannabis plants and the reported eradication of cannabis plants and production sites. The cannabis market in Europe is marked by high demand and a variety of products, the production of which is sometimes linked to violence and other criminal activities, as organized criminal groups have become involved in the trafficking of cannabis.

Even though domestic production of cannabis is widespread, there are still signs that it may not be sufficient to meet European market demand. For example, in the United Kingdom seizures at the border of both herbal cannabis and cannabis resin are increasing, while seizures of locally grown cannabis plants (sinsemilla) are decreasing. On the one hand, such trends may suggest that domestic production is not sufficient to satisfy demand, which may...
increasingly rely on imported products. On the other hand, the detection of cannabis plant cultivation sites, usually indoors, may have become a growing challenge for law enforcement, as there is an increasing tendency for criminal groups to run numerous small-scale cultivation sites rather than few large-scale plantations in order to mitigate the risk of detection.287

Although the prevalence of cannabis use remains high in Western and Central Europe (5.7 per cent), there is evidence of stabilizing or decreasing trends, especially in countries with long and established cannabis use. Information on the use of NPS in Europe is not comprehensive and does not establish whether the decrease in cannabis use is associated with the emerging use of synthetic cannabinoids or other NPS.

**Asia: cannabis consumption remains below global levels**

Cannabis consumption in Asia seems to continue to be below global levels, although reliable estimates of prevalence of use are available for only a few countries. Cannabis is the most common illicitly used substance in the region, with an annual prevalence of use among those aged 15-64 of 1.9 per cent. Experts perceive an increase in its use, but the quantities of herbal cannabis seized remained stable overall in most parts of Asia in 2013, totalling 292 tons. South Asia continued to account for the majority of the quantities of cannabis resin intercepted in the subregion, but countries in the Near and Middle East/South-West Asia reported that seizures of cannabis resin originating in Afghanistan were increasing. This trend continued in 2013, marking the increasing importance of Afghanistan in the global supply of cannabis resin and highlighting the fact that the same trafficking routes are being used for the smuggling of different substances. In 2013, Pakistan reported seizures of almost twice the quantity seized in 2012, mentioning Afghanistan as the source country for all the cannabis resin seized.

**Oceania: high levels of use, fed by domestic cultivation**

Information about drug use in Oceania is limited to Australia and New Zealand, where there are high levels of cannabis use (10.7 per cent annual prevalence of use). With a high frequency of cannabis experimentation and use within the general population, cannabis is the most widely used illicit drug in New Zealand and accounts for most illicit-drug-related hospital admissions. Cannabis cultivation remains a predominantly domestic matter in New Zealand, with no evidence of large-scale imports or exports of cannabis or any of its derivatives.

Cannabis is also the most common drug used (both past-year and lifetime use) in Australia, with prevalence and

---

Herbal cannabis continues to be the most seized illicit drug in Oceania. The quantity of herbal cannabis seized in Australia in 2013 was the highest reported in the past decade,289 whereas in New Zealand, it remained relatively stable. In Australia, the retail cannabis price has remained stable while THC content is thought to have increased in the past decade,290 suggesting a potential increase in the availability of the drug.

**Africa: increases in cannabis cultivation and production**

Cannabis cultivation, production, trafficking and use occur in all parts of Africa.291 There is only limited information available on the drug use situation in Africa, but the prevalence of cannabis use in the region is estimated to be high (7.5 per cent of the population aged 15-64) compared with the global average (3.9 per cent), and is particularly high in West and Central Africa (12.4 per cent). In 2013, Egypt, Morocco and Nigeria each reported seizing over 200 tons of cannabis herb. Between 1990 and 2011, Morocco reported the largest annual quantities of cannabis resin seized in North Africa and continued to seize significant quantities of cannabis resin in 2012 and 2013 (137 tons and 107 tons, respectively). Since 2012, however, with 157 tons intercepted in 2012 and 212 tons in 2013, Algeria is now reporting the largest annual quantities of cannabis resin seized in North Africa, which the country attributes to law enforcement efforts.292

---

**IS CANNABIS BECOMING MORE HARMFUL?**

Measured in terms of THC (Δ9-tetrahydrocannabinol) content, cannabis potency is often linked to how harmful cannabis may be. Higher THC content has been associated with anxiety, depression, an increased risk of dependence, psychotic symptoms and effects on the respiratory and cardiovascular systems, particularly among regular users, although anxiety or psychotic symptoms may also occur in recent and inexperienced users. A recent study in south London suggests the risk of psychosis is three times higher in users of high-potency herbal cannabis (“skunk”) than in non-users. The presence in cannabis of CBD (cannabidiol), a cannabinoid with anti-psychotic properties, may partially counterbalance the harm caused by THC. This interaction should be taken into account when analysing cannabis potency, yet CBD is not frequently monitored, which leads to difficulties in assessing the harm caused by cannabis and public health implications. Globally, cannabis potency data is very scarce, but in countries with available information there are signs of an increase in THC content, particularly in the past decade, and in cannabis-related health problems. A systematic review of THC content in herbal cannabis has suggested that it is increasing, although the increase is not constant and does not exceed 5 per cent globally. Reporting an average potency of over 10 per cent in 2012, most European countries experienced an increase in THC content, mainly in herbal cannabis, from 2006 to 2012. In the past two decades, there has also been a change in users’ preferences in Europe, most notably in the Central and Western part of the region, where cannabis markets are the largest. Data suggest a shift from cannabis resin to herbal cannabis, with increasing use of domestic, as opposed to imported, products, particularly sinsemilla (unfertilized female plants), characterized by high levels of THC and very low levels of CBD. The past decade has seen rapid advancement in cannabis plant cultivation techniques in some European countries, leading to the spread of domestic (indoor) cultivation, thereby reducing reliance on imported cannabis products. Indoor cannabis plant cultivation, using controlled growing conditions and genetically selected strains, has led to an increase in the number of harvests, as well as in yield available on the drug use situation in Africa, but the prevalence of cannabis use in the region is estimated to be high (7.5 per cent of the population aged 15-64) compared with the global average (3.9 per cent), and is particularly high in West and Central Africa (12.4 per cent). In 2013, Egypt, Morocco and Nigeria each reported seizing over 200 tons of cannabis herb. Between 1990 and 2011, Morocco reported the largest annual quantities of cannabis resin seized in North Africa and continued to seize significant quantities of cannabis resin in 2012 and 2013 (137 tons and 107 tons, respectively). Since 2012, however, with 157 tons intercepted in 2012 and 212 tons in 2013, Algeria is now reporting the largest annual quantities of cannabis resin seized in North Africa, which the country attributes to law enforcement efforts.292

---

Sources:

and potency. Selective breeding, which mainly focuses on achieving high THC content, has also resulted in the selection of varieties containing less CBD.

Data on cannabis samples sold in “coffee shops” in the Netherlands show that the THC content of the two most consumed cannabis products — imported cannabis resin and domestically produced (Dutch) herbal cannabis or *nederwiet* (mostly sinsemilla) — has stabilized at high levels (around 15 per cent) in recent years, while CBD content has remained low (under 1 per cent) in *nederwiet* but comparatively high in imported resin (7 per cent).

Even within a specific strain of cannabis there may be great variability in content, suggesting that users may be unwittingly exposed to very different levels of THC and CBD. Moreover, the change in users’ preferences, from traditional (seeded) herbal cannabis to sinsemilla, suggests an increased level of risk exposure in Europe.

Despite evidence of stabilizing or decreasing trends in the prevalence of cannabis use in Europe, particularly in countries with established levels of cannabis use, there are indications of increases in cannabis-related health problems. Between 2006 and 2012, the number of individuals (first admissions to drug treatment) seeking help for cannabis use in Europe rose from 45,000 to 59,000, nearly half of whom (49 per cent) were daily users; and cannabis has become the most frequent drug reported as the main reason for first-time entrants for treatment. Moreover, cannabis-related emergency episodes have seen an increase in Europe, particularly in countries with the highest prevalence of use.
of 14.5 per cent in 2013). Available data in the United States show an increasing trend in cannabis-related treatments in the past two decades, from 6.9 per cent in 1993 to 17.5 per cent in 2012, along with increasing cannabis-related hospital admissions.\(^9\)


c It should be noted that this is specific to "skunk", as other cannabis products may result in different risks.


g EMCDDA, Statistical Bulletin 2014.


m EMCDDA, European Drug Report 2014.


o G. Knight and others, "The results of an experimental indoor hydroponic Cannabis growing study, using the 'Screen of Green' (ScrOG) method-Yield, tetrahydrocannabinol (THC) and DNA analysis", Forensic Science International, vol. 202, Nos. 1-3 (2010), pp. 36-44.

p Mehmedic and others, “Potency trends of \(\Delta-9\)-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008” (see footnote 279).

q Ibid.
contrast to inhaled THC-containing products, which take effect after a few seconds or minutes, oral consumption has a delayed effect of between 30 and 90 minutes that lasts from 4 to 12 hours, far longer than psychotropic effects from inhalation, which last around 2 to 3 hours. This may lead to ingestion of greater quantities of THC than desired.⁷

Health impacts

According to the results of the United States National Survey on Drug Use and Health, the prevalence of marijuana use in Colorado is higher, and is increasing faster, than the national average. There is no causal evidence to connect legislation to prevalence of use, but peaks in past-year prevalence appear to coincide with laws easing restrictions on personal consumption.

Mirroring trends in prevalence of use of marijuana in Colorado, the number of primary treatment admissions per 100,000 is high and growing among persons aged 12 or older, and has exceeded the national average since 2003.

Reaching an average of 18.7 per cent, according to the laboratory responsible for state-mandated testing, the THC concentration of legally sold cannabis in Colorado is relatively high.⁸ Perhaps serving as an early indicator of the acute effects of increased access to high-potency marijuana and THC-containing products, calls to the Rocky Mountain Poison and Drug Center concerning marijuana doubled between 2013 and 2014. In addition, emergency room data indicate that there has been a number of severe burns from attempted THC extraction from cannabis plants and cyclic vomiting caused by the ingestion of high THC-content products (cases doubled following medical marijuana legalization), and unintentional marijuana ingestion among children (from zero in the five years prior to medical liberalization, to 14 between 2009 and 2011, among admissions to the Children’s Hospital of Colorado).¹

Moreover, according to the Colorado State Patrol, marijuana was related to 12.2 per cent of all citations for driving under the influence of any substance in 2014, while among road accidents involving fatalities the number of drivers who tested positive for marijuana doubled from 37 in 2006 to 78 in 2012. It will, however, be several years before any change specifically attributable to retail marijuana sales and traffic deaths is evident.

Criminal justice

As expected, arrests for possession (2 ounces or less) and cases brought to state court declined significantly from 2012 to 2013 across Colorado, freeing law enforcement resources otherwise spent on making marijuana-related arrests, whereas marijuana-related arrests in the border counties of the neighbouring state of Nebraska have increased significantly.¹² Arrests at Colorado schools¹³ for marijuana charges have also increased, although only slightly, from 273 in 2012/13 to 289 in 2013/14, but several years of data will be required before the impact of commercially available marijuana on youth behaviour can be properly interpreted.

State revenues

Following strong growth in 2014, monthly tax revenues from the retail and medical marijuana markets in the state
of Colorado ended at nearly triple the revenue earned in January, bringing in over $8.5 million in the month of December alone. In revenue from sales, licences and fees in both the medical and retail marijuana markets, the state is poised to net approximately $76 million\(^w\) in the 2014 calendar year.

- To be consistent with legal language from bills pertaining to cannabis as "marijuana" throughout the Americas, the term marijuana in the present section of the report refers to all cannabis products and in some cases tetrahydrocannabinol (THC) containing products.
- Data from Amendment 64: Use and Regulation of Marijuana (United States, Constitution of the State of Colorado, art. XVIII, sect. 16).
- United States, State of Alaska, Ballot Measure No. 2: 13PSUM An Act to Tax and Regulate the Production, Sale, and Use of Marijuana.
- United States, State of Oregon, Measure 91: Control, Regulation, and Taxation of Marijuana and Industrial Hemp Act.
- United States, District of Columbia, Ballot Initiative No. 71, which took effect in July 2014, will allow up to 2 ounces of marijuana and cultivation of up to six plants. As the District of Columbia does not have statehood, thereby falling under Federal governance, this initiative may not fall under the same provision as those of states.
- Jamaica, Dangerous Drugs (Amendment) Act, 2015.
- United States, Constitution of the State of Colorado, 0-4-287, art. XVIII, miscellaneous art. XVIII.
- See United States, Department of Justice, "Memorandum for selected United States attorneys on investigations and prosecutions in states authorizing the medical use of marijuana", 19 October 2009.
- In November 2012, Colorado voters passed Constitutional Amendment 64, which legalized marijuana for recreational purposes for anyone over 21 years of age. Retail stores opened on 1 January 2014.
- United States, State of Colorado, Department of Revenue.

\[^w\]Demand estimates for 2014 were based on the prevalence of past-year users estimated by the National Survey on Drug Use and Health (NSDUH) 2010 and 2011 survey results, stratified by frequency of use and adjusted for population growth (5.3 per cent) and underreporting (22.2 per cent adjustment among users who use 20 days or less per month and 11.1 per cent for those who use more frequently), see Miles K. Light and others, "Market size and demand for marijuana in Colorado" (July 2015), prepared for the Colorado Department of Revenue, p. 15.

\[^n\]Light and others, "Market size and demand for marijuana in Colorado" (July 2015), prepared for the Colorado Department of Revenue.

\[^o\]The total amount estimated for use (130.3 tons) includes an estimated 121.4 tons for residents and 8.9 tons for visitors. The quantity of marijuana in demand for the estimated 184,000 residents under the age of 21 who reported use in the past year was not included.

\[^p\]Light and others, "Market size and demand for marijuana in Colorado" (see footnote 210).


\[^s\]"State mandated testing of retail marijuana in Colorado", presentation made by Andy LaFrate from Charas Scientific to the 249th American Chemical Society National Meeting and Exposition, Denver, Colorado, March 2015.


\[^u\]J. M. Ellison and R. Spohn, "Colorado’s legalization of medicinal marijuana: the effects on Nebraska’s law enforcement and local jail system" (Nebraska Center for Justice Research, University of Nebraska at Omaha, 2015).

\[^v\]United States, Denver Police Department Versadex and OSI databases.

\[^w\]United States, Colorado Department of Revenue.
CHAPTER I
Synthetic drugs

SYNTHETIC DRUGS: amphetamine-type stimulants and new psychoactive substances

Key figures

The global market for synthetic drugs, which for the purposes of the present report includes amphetamine-type stimulants (ATS) and new psychoactive substances (NPS), continues to be dominated by methamphetamine, with East and South-East Asia accounting for the largest seizures reported worldwide. The market for methamphetamine is becoming increasingly diversified. In addition to the established and growing market for methamphetamine in East and South-East Asia, there are also indications of increasing use in parts of North America and Europe. Seizure data for “ecstasy” and its precursor chemicals point to the growing availability of “ecstasy” in East and South-East Asia.

Regarding the large numbers of NPS which have emerged in recent years, it remains unclear whether they are displacing existing drugs under international control, in either the short or long term, or whether they are diversifying the range of synthetic drugs available on the market. Although prevalence figures for synthetic cannabinoids in the United States and mephedrone in the United Kingdom suggest declining use of these substances, a growing number of countries has been reporting a wider range of emerging NPS and worrying developments such as the injecting use of NPS. Up to December 2014, a total of 541 NPS were reported to the UNODC early warning advisory by 95 countries and territories, through data submissions from Member States and national drug testing laboratories participating in the international collaborative exercises programme. While there are large numbers of NPS available on the synthetic drugs market globally, emergence and persistence patterns of these substances show significant differences between countries and regions.

293 For the purpose of the present report, the term “synthetic drugs” includes ATS, the main drugs being amphetamine, methamphetamine and “ecstasy”–type substances, and NPS.

294 For the purpose of the present report, the analysis of NPS includes ketamine, which differs from other NPS in that it is widely used in human and veterinary medicine, while most NPS have little or no history of medical use.

295 UNODC, early warning advisory on NPS.
Methamphetamine is driving the increase in ATS seizures

Surging seizures since 2009 point to a rapid expansion of the global ATS market, with ATS seizures almost doubling to reach over 144 tons in 2011 and 2012 — the highest ATS seizure amounts since UNODC systematic monitoring began — before decreasing slightly in 2013 (see figure 69). The increase from 2009 is primarily attributable to the growing amount of methamphetamine seized, which increased from 34 tons in 2009 to 88 tons in 2013. The growing importance of methamphetamine is a rather recent feature of the global ATS market. Over the years, global amphetamine seizures have fluctuated, ranging between about 20 tons and 33 tons annually since 2009. Global “ecstasy” seizures were low compared with amphetamine and methamphetamine seizures and remained under 5 tons annually between 2009 and 2013.

Increasing interconnections in the methamphetamine market

While methamphetamine continues to be primarily trafficked within regions, significant increases in methamphetamine seizures observed in the past five years would seem to indicate the establishment of new trafficking routes linking previously unconnected regional methamphetamine markets (see map 3). New international supply channels linking major methamphetamine markets in North America and East and South-East Asia have been observed. In addition, methamphetamine trafficking routes to East and South-East Asia have emerged from several parts of Africa and the Americas. West Africa in particular appears to have become an established source of methamphetamine trafficked to East and South-East Asia via South Africa or Europe. Turkey may have emerged

MAP 3. Methamphetamine flows as perceived by recipient countries, 2011-2013


Note: The origins of the flow arrows do not necessarily indicate the source/manufacture of methamphetamine. These arrows represent the flows as perceived by recipient countries. Flow arrows represent the direction of methamphetamine trafficking and are not an indication of the quantity trafficked. The boundaries shown on this map do not imply official endorsement or acceptance by the United Nations. Dashed lines represent undetermined boundaries. The dotted line represents approximately the Line of Control in Jammu and Kashmir agreed upon by India and Pakistan. The final status of Jammu and Kashmir has not yet been agreed upon by the parties. The final boundary between the Sudan and South Sudan has not yet been determined.
as a transit point for methamphetamine smuggled from Western Asia to Western and Central Europe. Recently, there have also been reports of methamphetamine trafficking from Western and Central Europe to North America, South America and East and South-East Asia.

New trends in methamphetamine use

Methamphetamine use continues to be a major problem in large parts of East and South-East Asia and accounts for a large share of people receiving drug treatment in a number of countries in the subregion. In 2013, people receiving treatment for methamphetamine use accounted for the majority of people treated for drug use in many countries.296,297

Methamphetamine use in the United States displays a stable trend, with annual prevalence of methamphetamine use among the general population aged 15-64 having remained in the range of 0.5 to 0.6 per cent between 2010 and 2013. However, there are recent indications of increases in methamphetamine use in certain parts of the United States. In Minneapolis/Saint Paul, a 19 per cent increase in the number of people treated for methamphetamine use between 2011 and 2012 was reported.298 In the state of Ohio, there was a 34 per cent increase in the number of people receiving treatment for methamphetamine use between 2009 and 2012.299 In San Diego, deaths related to methamphetamine use have increased by more than 70 per cent between 2008 and 2012.300

In Europe, while amphetamine and “ecstasy” continue to account for the bulk of ATS seizures, there appears to be increasing availability of crystalline methamphetamine, including in countries where reports on the use of methamphetamine have not been common in the past. According to the Federal Criminal Police Office in Germany, the number of first-time crystalline methamphetamine users increased by almost 7 per cent to 2,746 users in 2013, crystalline methamphetamine seizure cases rose by about 10 per cent to 3,847 cases and the quantity of the drug seized increased by 88 per cent to 75.2 kg in the same year.301 The results of a survey in Frankfurt, Germany, found high methamphetamine use among people in the techno-party scene in 2012.302 According to EMCDDA, there have been new reports from Greece and Turkey of the smoking of methamphetamine.303 In Greece, crystalline methamphetamine seizures increased from only 1 kg in 2012 to 15 kg in 2013 and, according to the Turkish National Police, crystalline methamphetamine makes up the majority of methamphetamine seizures in the country.304 EMCDDA also reports an emergence of crystalline methamphetamine smoking among people who inject opioids in southern European countries.305

For some years, methamphetamine has dominated the market in the Czech Republic and Slovakia. However, in 2013, methamphetamine seizures not only accounted for the largest share of ATS seizures reported in the Czech Republic and Slovakia, but also in some countries in the Baltics and Eastern Europe, such as Belarus, Latvia, Lithuania and the Republic of Moldova, as well as Cyprus, Greece and Portugal.

A diversified market for methamphetamine in East and South-East Asia

The methamphetamine sold in East and South-East Asia is presented in two main forms: methamphetamine tablets and crystalline methamphetamine. In both cases, methamphetamine is available in salt form, most frequently as methamphetamine hydrochloride, which, in principle, can be smoked, nasally insufflated, orally ingested and injected. Methamphetamine tablets, commonly known as “yaba” in the subregion, are small pills, typically of low purity, which are available in many different shapes and colours. In addition to methamphetamine, such tablets often contain a large portion of caffeine, plus a range of adulterants. In the case of methamphetamine tablets, both ingestion and smoking of the crushed tablets are common. Crystalline methamphetamine, also called “crystal meth”, “ice” or “shabu”, is usually of much higher purity than the tablet form. It is encountered on the illicit drug market as (crushed) colourless crystals of different sizes. In the case of crystalline methamphetamine, smoking, nasal insufflation and injecting are typical forms of consumption.306

Information on seizures and use indicate that the market for both forms of methamphetamine is expanding. Seizures of methamphetamine tablets and crystalline methamphetamine generally increased in East and South-East Asia between 2008 and 2013 (see figure 70). Crystalline methamphetamine seizures in the region almost doubled over this period, while methamphetamine tablet seizures have risen at a more rapid rate resulting in an eight-fold increase.

---

296 Based on data collected by the Drug Abuse Information Network for Asia and the Pacific.
297 Ibid.
298 United States, DEA, National Drug Threat Assessment Summary, November 2014.
299 Ibid.
300 Ibid.
305 EMCDDA, European Drug Report 2014.
306 Terminology and Information on Drug (United Nations publication, Sales No. E.03.XI.13); Recommended Methods for the Identification and Analysis of Amphetamine, Methamphetamine and Their Ring-Substituted Analogues in Seized Materials: Manual for Use by National Drug Testing Laboratories (United Nations publication, Sales No. E.06.XI.1).
Number of methamphetamine tablets

307 Based on expert perception on the use of main drugs of concern has evolved in recent years. For a number of years, crystal-methamphetamine originating in other parts of the world a complex international trafficking pattern of crystalline manufactured on a large scale in East and South-East Asia,

Although crystalline methamphetamine continues to be manufactured on a large scale in East and South-East Asia, a complex international trafficking pattern of crystalline methamphetamine originating in other parts of the world has evolved in recent years. For a number of years, crystal-

307 UNODC, Patterns and Trends of Amphetamine-type Stimulants and other Drugs: Challenges for Asia and the Pacific (November 2013); UNODC, Global Synthetic Drugs Assessment: Amphetamine-type Stimulants and New Psychoactive Substances (Vienna, 2014).

310 “Indonesia country report”, presented by the National Narcotics Board of Indonesia at the Global SMART Programme regional meeting, Yangon, 20 and 21 August 2014; National Police Agency of Japan, October 2014; Malaysia drug situation report, presented by the Royal Malaysian Police at the Twenty-fourth Anti-Drug Liaison Officials’ Meeting for International Cooperation, Jeju, Republic of Korea, 1-3 October 2014; and “Thailand country report”, presented by the Office of the Narcotics Control Board of Thailand at the Nineteenth Asia-Pacific Operational Drug Enforcement Conference, held in Tokyo from 18 to 20 February 2014.

311 Information provided by International Safety and Security Cooperation Division, Ministry of Foreign Affairs, Japan, August 2014; National Police Agency of Japan, October 2014.

312 Presentation by the Philippine Drug Enforcement Agency at the Nineteenth Asia-Pacific Operational Drug Enforcement Conference, held in Tokyo from 18 to 20 February 2014; presentation by the Supreme Prosecutors’ Office of the Republic of Korea, at the Global SMART Programme regional meeting, Yangon, 20 and 21 August 2014; presentation by the Australian Federal Police at the Nineteenth Asia-Pacific Operational Drug Enforcement Conference, held in Tokyo from 18 to 20 February 2014.


314 Ibid.

Regional shift in the “ecstasy” market?

In 2012, “ecstasy” seizures in East and South-East Asia and Oceania surged to almost 2 tons, just under the 2.3 tons seized in Europe, but much higher than the 0.7 tons seized in the Americas. East and South-East Asia and Oceania may be becoming an emerging driver of the global market for “ecstasy”, while seizures in the Americas have declined, dropping by 81 per cent between 2009 and 2012. Although “ecstasy” seizures in East and South-East Asia and Oceania declined to 1 ton in 2013, seizures continued to be at a higher level than in 2008-2011, and in 2014 multi-ton seizures were reported by law enforcement authorities in Australia and Myanmar.

Insufficient data are available to establish the size of the “ecstasy” market based on use figures for East and South-East Asia and Oceania. Nevertheless, data on specific population groups suggest widespread use in certain countries. In Indonesia, a national survey among transportation workers in 2013 found that, at 1.4 per cent annual prevalence of use, “ecstasy” was the second most used drug after cannabis at 4.9 per cent. At 1.3 tons, Indonesia reported the largest quantity of “ecstasy” seizures in the world in 2012, which was reportedly intended in its entirety for supplying the domestic market. This points to the presence of a large amount of “ecstasy” in the country in that year.

There have also been indications of “ecstasy” use emerging in the Mekong region. According to expert perceptions in 2012, “ecstasy” use had increased in Cambodia, Thailand and Viet Nam. Although low levels of “ecstasy” seizures were reported in Cambodia and Thailand, seizures in Viet Nam increased to almost 0.2 tons in 2012.

The large amount of MDMA chemical precursors recently seized in East and South-East Asia and Oceania implies that there may be considerable “ecstasy” manufacture in these subregions. Based on commonly used MDMA manufacturing methods, as outlined by the International Narcotics Control Board, the almost 66,000 litres of safrole and 3,4-MDP-2-P seized in the region in 2011 and 2012 could theoretically have been sufficient to produce about 44 tons of “ecstasy”. This amount far exceeds the total “ecstasy” seized worldwide in both 2011 and 2012, which amounted to 9 tons. Although “ecstasy” is manufactured in East and South-East Asia and Oceania, a decreasing number of “ecstasy” trafficking attempts from these countries are being intercepted in other parts of the world (see figure 71).

Links and interaction between new psychoactive substances and other drugs

In the past few years, a growing number of NPS have been sold on illicit drug markets. NPS available on the market may or may not share effects and profiles similar to the substances under international control that they are designed to mimic.

Only limited data series are available that allow the comparison of prevalence of use trends of NPS and other drugs. The annual prevalence of cannabis use among twelfth-grade students in the United States remained stable at 36.4 per cent between 2011 and 2013 and declined only slightly in 2014 to 35.1 per cent, while synthetic cannabinoid (“spice”) use almost halved from 11.4 per cent in 2011 to 5.8 per cent in 2014 (see figure 72). The perceived harmfulness of synthetic cannabinoids among secondary school students (twelfth grade) increased between 2012, the first year of measurement, and 2014, which may have contributed to the decline in use. Data from a recent qualitative study suggest that use of both herbal cannabis and synthetic cannabinoids may not be uncommon. Users may choose one or the other depending on

316 Official government communication by the Central Committee for Drug Abuse Control of Myanmar, March 2015.
319 For more information, see UNODC, The Challenge of New Psychoactive Substances (Vienna, March 2015).
For some time, the market for “ecstasy” has been on the decline in several European countries and mephedrone and other NPS may have been serving as a substitute for “ecstasy”. However, annual prevalence data for the United Kingdom show that mephedrone use may have fallen below that of “ecstasy” in recent years (see figure 73). Between 2010 and 2013, annual prevalence rates of both “ecstasy” use and mephedrone use among people aged 16-24 in the United Kingdom have been on the decline. Mephedrone use among this population segment fell by almost two thirds from 4.4 per cent in 2010/11 to 1.6 per cent in 2012/13, while “ecstasy” use declined only from 3.8 per cent to 2.9 per cent over the same period. Although the prevalence of mephedrone use among people aged 16-24 in 2010/11 was 0.6 percentage points higher than that of “ecstasy”, by 2012/13 “ecstasy” use was almost twice as high as mephedrone use.

Despite a possible decline in the overall demand for mephedrone in the United Kingdom, high levels of use have been observed among some segments of the population. Mephedrone use appears to be particularly common in London dance clubs. Indeed, in the Crime Survey for England and Wales in 2012/13, at 4.4 per cent the highest mephedrone use rate was found among adults who had visited a nightclub on four or more occasions in the past month. Similarly, another survey of visitors to nightclubs in Rome in 2013 found that NPS were being used in addition to drugs such as cocaine. Polydrug use can involve unpredictable effects and poses a serious challenge for health-care providers.

According to EMCDDA, there has been a decline in the injecting of illicit drugs in Europe, but there have been recent reports of the injecting of NPS, particularly synthetic cathinones. For instance, based on reports from the treatment and needle and syringe programmes in Hungary, synthetic cathinone injecting has increased since 2010, while injecting heroin use has declined. By 2012, the number of people in Hungary treated for injecting synthetic cathinone use accounted for about 34 per cent of people in that programme. Moreover, a needle and syringe programme in Bucharest reported in 2012 that 51 per cent of people in the programme injected NPS (primarily synthetic cathinones), 44 per cent injected heroin and 5 per cent injected both NPS and heroin. In Austria, a survey among people receiving treatment for drug use in Graz in 2010 identified that almost 60 per cent of people were injecting mephedrone, and the use of the

---


322 While no clear link has yet been established, government activities aimed at raising awareness about the health risks associated with using NPS and the introduction of national controls for mephedrone, scheduled as a class B drug under the Misuse of Drugs Act in 2010, took place simultaneously.


325 EMCDDA, “Perspectives on drugs: injection of synthetic cathinones”, Perspectives on Drugs Series, 27 May 2014.


327 See footnote 325.

328 Marion Weigl and others, 2012 National Report (2011 Data) to the
synthetic cathinone 4-MEC\textsuperscript{329} by people who inject drugs in Paris was reported in 2012.\textsuperscript{330} EMCCDDA has also reported that injecting use of synthetic cathinones has emerged among specific population segments in Austria, Belgium, the Czech Republic, France, Germany, Ireland, Poland, Romania, Spain and the United Kingdom.\textsuperscript{331}

Use data for NPS at the substance level are still limited. Among the reasons for this are that there is a large number of different NPS available on the market, and some of them are sold under street names that could imply a variety of different substances. For instance, the term “spice”, often used in reference to the use of synthetic cannabinoids, does not relate to a specific substance and could instead refer to a large variety of substances. Given that users can often not identify their actual substance of use, other sources of information gain in importance. Information emerging from early warning systems on NPS has helped to identify the use of NPS and associated health risks at an early stage.\textsuperscript{332} In Sweden, for example, a toxicovigilance system documented widespread use of many different NPS mainly by adolescents and young male adults.\textsuperscript{333} Based on its European early warning system on NPS, EMCCDDA has undertaken an increasing number of risk assessments of NPS (eight in 2014 alone, compared with only two in the period 2009-2013), documenting the presence of NPS associated with serious negative health consequences in the region.\textsuperscript{334} Early warning systems on NPS have also been established in a number of other countries to make information available on the emergence of NPS, health risks associated with their use and best practices to respond to those risks.

**Number of new psychoactive substances reported**

By December 2014, 95 Member States and territories had reported the emergence of NPS to the UNODC early warning advisory under the global Synthetics Monitoring: Analysis, Reporting and Trends (SMART) programme, with notable variations in the number and type of NPS encountered (see figure 74).\textsuperscript{335} The four countries or territories that reported for the first time in 2014 were the Cayman Islands (Americas), Montenegro (Europe), Peru (Americas) and Seychelles (Africa). The majority of countries and territories that reported the emergence of NPS up to December 2014 were from Europe (39), Asia (27), Africa (14), the Americas (13) and Oceania (2).

Up to December 2014, a total of 541 NPS had been reported to the UNODC early warning advisory (see figure 75). In 2014, 450 substances were reported, an increase from the 430 substances reported in 2013. Although this does not indicate a major increase, it is noteworthy that of the 450 substances reported in 2014, 69 were reported to the advisory for the first time. The large increase in NPS reported to the advisory between 2012 and 2013 was due to the expansion of data sources and data completeness in the system as well as increasing laboratory capacity to identify NPS.

In 2014, synthetic cannabinoids continued to account for the majority of NPS reported (39 per cent), followed by phenethylamines (18 per cent) and synthetic cathinones (15 per cent) (see figure 76). More synthetic cannabinoids and, to a lesser extent, synthetic cathinones were reported in 2014 than in 2013, with the majority of the other NPS substance groups remaining stable. Some decreases have been identified regarding NPS belonging to ketamine and phencyclidine-type substances, with only half the number reported in 2013 being reported in 2014 and a slight decrease in the number of reports for tryptamines. Of all reported substances in 2014, 69 were reported to the UNODC early warning advisory for the first time, including 25 synthetic cannabinoids, 16 phenethylamines and synthetic cathinones, 8 other substances and 2 aminoindanes and tryptamines.

\textsuperscript{329} 4-MEC is the chemical abbreviation of 4-methylethcathinone, a synthetic cathinone not under international control.


\textsuperscript{331} EMCCDDA, “Perspectives on drugs: injection of synthetic cathinones”, Perspectives on Drugs Series, 27 May 2014.


\textsuperscript{334} EMCCDDA website, publication search.

\textsuperscript{335} All data in the present section of this report were extracted from the UNODC early warning advisory on NPS, available at www.unodc.org/nps, unless otherwise indicated.
Using the early warning advisory for NPS, different patterns in the emergence and persistence of these substances have been identified. There is frequently heterogeneity in the emergence of NPS at the country level, even within regions; that is, the overlap between different NPS found in one country and in a neighboring country within a given period of time can be small. Some NPS have an established presence on the market and have been reported by a large number of countries over several years. These include ketamine (58 countries), khat (51 countries), mephedrone (46 countries) and JWH-018 (44 countries).

More than a quarter of all countries reporting the emergence of NPS worldwide have reported only one substance, most of which were reports of plant-based NPS and ketamine. About 47 per cent of countries reporting the emergence of NPS have identified 10 substances or less, while approximately 18 per cent have identified more than 100 different NPS since 2008.

Synthetic cannabinoids: the challenge of diversity

Synthetic cannabinoid receptor agonists, commonly referred to as synthetic cannabinoids, constitute the largest, most diversified and fastest growing group of NPS on the market. Since 2004, many different synthetic cannabinoids have been detected in herbal smoking blends sold on the Internet and in specialized shops under a variety of brand names. These products typically contain dried and shredded plant material with no intrinsic psychoactive properties, but which is soaked in or sprayed with one or several synthetic cannabinoids.

In 2014, 177 different synthetic cannabinoids were reported to the UNODC early warning advisory. The emergence of products containing synthetic cannabinoids on the market is not a new phenomenon; however, it is only since 2008 that their use has gained increasing popularity as "legal cannabis substitutes". Since then, the emergence of hundreds of products containing different synthetic cannabinoids has been reported to the advisory by 58 countries and territories, and the attention of the international community has been drawn to their clandestine manufacture, the serious risks they pose to public health and society and the challenges for drug control.

Since the discovery of the cannabinoid receptors CB1 and CB2 in the 1980s, there has been continued growth and evolution of a series of chemical families of synthetic cannabinoids. Their emergence on the NPS market has been characterized by the introduction of successive structural modifications seemingly to keep their legal status ambiguous. This can be illustrated by the emergence of naphthoylindoles (e.g. JWH-018) and the more recent emergence of naphthoylindazoles (e.g. THJ-018) and indazole carboxamides (e.g. AKB-48).336

The structural diversity and rapid development of new derivatives of synthetic cannabinoids pose serious challenges to legislative control at the national and international levels. In response to these challenges, innovative legal approaches complementing the traditional control of drugs have been adopted at the national level by some countries to protect the population from health risks caused by the open sale of synthetic cannabinoids. An

336 For more information, see UNODC, “Synthetic cannabinoids in herbal products” (Vienna, 2011).
example of this approach is the control of synthetic cannabinoids based on their effect on the brain recently used in some countries, including the United States and Luxembourg. The United States introduced the neurochemical approach to control synthetic cannabinoids or “cannabinoid mimetic agents”, under the Synthetic Drug Abuse Prevention Act 2012 and defined them as “any substance that is a cannabinoid receptor type 1 (CB1 receptor) agonist as demonstrated by binding studies and functional assays” within defined structural classes. The definition includes a group of substances with possible chemical variations, but which have a specific effect through binding to the CB1 receptor.

During its fifty-eighth session, in March 2015, the Commission on Narcotic Drugs decided to place 10 NPS under international control, among them two synthetic cannabinoids, JWH-018 and AM-2201, which were added to Schedule II of the Convention on Psychotropic Substances of 1971.

The transient nature of new psychoactive substances

Although a growing number of NPS are being reported by a larger number of countries every year, some NPS are found to be transient. For instance, of the 541 NPS reported up to December 2014, 16 substances had not been reported since 2012 and 49 had not been reported since 2013. Several NPS have only been reported by a small number of countries in a particular year and some substances seem to have disappeared from the market entirely. For example, the tryptamine 5-MeO-DPT was reported by eight countries between 2009 and 2012, but since then there have been no further reports of its availability by countries submitting to the UNODC early warning advisory. Other substances such as the synthetic cannabinoid CP-series have shown large variations in market availability since 2009. For example, the CP-47,497 series was first reported by four countries in Europe in 2009, but in 2012 only two countries in Europe reported its presence to the advisory, whereas 10 countries reported its presence in 2013, as did six countries in 2014. Compared with other synthetic cannabinoids (e.g. aminoalkylindoles), the synthesis of non-classical cannabinoids such as the CP-series is elaborate and complicated, which may have influenced this pattern.

Enhancing efforts for an integrated response

The market for synthetic drugs is expanding and is becoming increasingly interconnected. Moreover, the synthetic drugs market has become increasingly diversified with a growing number of NPS available worldwide and an expanding market for crystalline methamphetamine in the United States and Europe. Further information and data are needed, however, to improve analysis of the relationship between NPS and substances under international control, while continuing to monitor emerging developments in the NPS market. Data on recent developments in polydrug use and injecting drug use involving NPS also remain limited. As these particular forms of drug use pose a serious challenge for treatment and health-care providers, information exchange and enhanced cooperation at the national and regional levels is crucial for establishing an effective response. Given the rapidly changing nature of the synthetic drugs market, there is a continued need for analysis of the scope and magnitude of the synthetic drugs problem based on forensic and scientific data and qualitative information.

H. CONCLUSIONS

Drug-use prevention and treatment: a change of perspective

New data remain insufficient to determine if substantial changes have occurred in the magnitude of drug use globally. Information is available only for western countries and does not reflect the situation in the highly populated regions of Asia and Africa. Yet the fact that an estimated 27 million people worldwide suffer from drug-use disorders shows that a large population is in need of health interventions, although only one in six of these people has access to treatment. A growing body of research has highlighted that drug-related health interventions can be effective and State and non-State actors now have the scientific basis for planning appropriate interventions.

Research shows the need to rethink drug-prevention strategies and shift the focus from counter-productive, fear-arousing messages to a more positive approach recognizing that children and youth start to use drugs in the context of personal or environmental vulnerabilities that are largely out of their control. Effective drug prevention can provide children and youth with the skills and opportunities to develop safe and healthy behaviour in their families, schools and communities.

There is no cure-all remedy for problem drug use. Drug use is a multi-faceted chronic health condition that requires long-term and continued care. Likewise, there is a need to revisit how success in drug treatment is measured, as treatment effectiveness on a person’s overall well-being can be evaluated only when the treatment is ongoing, not before or after treatment.

Where are increased quantities of opiates going?

The cultivation and production of opiates has been steadily increasing since 2009, reaching record levels in 2014.
But existing data on seizures and opiate use do not yet reveal a big shift in the global opiate market beyond the United States, where a resurgence in the heroin market is currently under way. The apparent stabilization in trafficking and demand for opiates can be explained by the fact that opiates may take a few years to reach destination countries, or that changes in the demand for opiates are going undetected. For example, Africa is being increasingly targeted by traffickers as a transit hub for heroin from Afghanistan and may be developing into a non-negligible consumption market.

Afghanistan is supplying 90 per cent of Canada’s heroin and may be increasingly supplying the United States. Seizures indicate that heroin from Afghanistan currently accounts for relatively few cases in the United States, but this may be changing. The reach of organized criminal networks is increasingly global and organized criminal groups are increasingly sophisticated and versatile, posing new challenges for national law enforcement agencies, whose strategies and interventions need constant revision. A prime example is the dark net, an anonymous online marketplace used for the illicit sale of a wide range of products including drugs. International cooperation and inter-agency collaboration has proved crucial in countering drug trafficking on the dark net but, as dark web technology grows and becomes increasingly accessible, and drug trafficking moves increasingly into the dark markets, such interventions may need to be rethought.

**Changing the perception of cannabis**

Amid the growing public debate on the advantages and disadvantages of the legalization of cannabis, and in the context of its actual legalization in some States, there is growing evidence that it is time to change the widespread perception of cannabis as an illicit drug without serious health consequences. The current cannabis market is far more complex and sophisticated than in the past and there is a far larger variety of cannabis products on the market than ever before, some of which appear to be more harmful than their predecessors. Highly potent strains of herbal cannabis, such as sinsemilla, which have high THC content (the main psychoactive ingredient) coupled with low CBD content (a cannabinoid with anti-psychoactive properties), are becoming increasingly popular in some markets. Given that there is growing evidence of links between cannabis use and some forms of mental illness, these developments may lead to even greater morbidity; an issue worthy of close monitoring.

**New psychoactive substances: taking a pragmatic approach to the problem**

Different countries report that NPS continue to proliferate in the marketplace, in terms of both quantity and diversity, although some are of a transient nature and disappear as quickly as they materialize. However, the paucity of data on the harmfulness and prevalence of use of NPS makes it difficult to facilitate risk assessment at the international level. There is an overriding challenge requiring enhanced efforts by some countries to understand whether or not certain NPS are replacing other “traditional” drugs, either in the short or the long term, or if they are merely supplementing the range of existing drugs under international control. There is also a need to identify the most prevalent, most persistent and most dangerous of the some 500 potentially harmful NPS that require action at the international level. Little may be known about the size and nature of the increasingly diversified NPS market, but given that injecting NPS poses a particular health threat to users, this rapidly evolving and dynamic phenomenon requires an adequate response.

**Time to consider prison health an integral part of public health**

Drug use, including injecting drug use, takes place in the prison environment. In some countries, there is clear evidence that drug use is higher among prison populations than in the community outside. Prison is a high-risk, controlled environment where drug use is prohibited but it can occur and often does so in unsafe conditions. Prison environments are characterized by high levels of infectious diseases (in particular HIV, but also hepatitis C and tuberculosis) as well as limited access to prevention and treatment, which increases the risk of contracting blood-borne viruses. The rapid turnover of a large number of people between the prison environment and the wider communities outside prison calls for strategies that consider prison health an integral part of public health, with a corresponding level of continuity of care. Equality of care for people held in prisons is a basic right guaranteed under international law.

**Premature deaths remain unacceptably high among people who inject drugs**

Among all people who use drugs, PWID face some of the most negative health outcomes. In spite of the fact that effective, evidence-based interventions are available for preventing overdose deaths and for the prevention, treatment and care of PWID living with HIV, premature death is common among this group. Considering that overdose deaths are preventable, continued efforts could address this through a number of interventions. Prime among these is the administration of naloxone, which can immediately reverse the effects of opioid overdose. Making naloxone available and easily accessible, and empowering first aid workers and drug users’ peers and family members with the necessary skills to administer naloxone, is a life-saving intervention. The health consequences of injecting drug use go beyond the risk of overdose and in many regions and countries, PWID experience high levels of HIV infection. There is therefore an urgent need to scale up evidence-based comprehensive harm reduction services to reach the goal of ending AIDS by 2030.